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ABSTRACT OF THE DISSERTATION 
SYNTHETIC STUDIES OF AZULENYL AND PSEUDOAZULENYL NITRONES 
by 
Amolkumar Kolhe 
Florida International University, 2009 
Miami, Florida 
Professor David Becker, Major Professor 
Free radicals have been implicated in various pathological conditions such as, 
stroke, aging and ischemic heart disease (IHD), as well as neurodegenerative diseases 
like Alzheimer’s, Parkinson’s, and Huntington’s disease. The role of antioxidants in 
protection from the harmful effects of free radicals has long been recognized. Trapping 
extremely reactive free radicals and eliminating them from circulation has been shown to 
be effective in animal models. Nitrone-based free radical traps have been extensively 
explored in biological systems. Examples include nitrones such as PBN, NXY-059, 
MDL-101,002, DMPO and EMPO. However, these nitrones have extremely high 
oxidation potentials as compared to natural antioxidants such as Vitamin E (α-
tocopherol), and glutathione. Becker et al. (1995) synthesized novel azulenyl nitrones, 
which were shown to have oxidation potentials much lower than that of any of the 
previously reported nitrone based spin traps. Another azulenyl nitrone derivative, 
stilbazulenyl nitrone (STAZN), was shown to have an even lower oxidation potential 
within the range of natural antioxidants. STAZN, a second generation free radical trap, 
was found to be markedly superior than the two most studied nitrones, PBN and NXY-
059, in animal models of cerebral ischemia and in an in vitro assay of lipid peroxidation.   
  vii 
 In this study, a third generation azulenyl nitrone was synthesized with an electron 
donating group on the previously synthesized STAZN derivative with the aim to lower 
the oxidation potential even more. Pseudoazulenes, because of the presence of an annular 
heteroatom, have been reported to possess even lower oxidation potential than that of the 
azulenyl counterpart. Therefore, pseudoazulenyl nitrones were synthesized for the first 
time by extracting and elaborating valtrate from the roots of Centranthus ruber (Red 
valerian or Jupiter’s beard). Several pseudoazulenyl nitrones were synthesized by using a 
facile experimental protocol. The physical and biological properties of these 
pseudoazulenyl nitrones can be easily modified by simply changing the substituent on the 
heteroatom.  
Cyclic voltammetry experiments have shown that these pseudoazulenyl nitrones 
do indeed have low oxidation potentials. The oxidation potential of these nitrones was 
lowered even more by preparing derivatives bearing an electron donating group at the 3-
position of the five membered ring of the pseudoazulenyl nitrone.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  viii 
TABLE OF CONTENTS 
CHAPTER                 PAGE 
1. Introduction ..................................................................................................... 1       
      1.1 History ..................................................................................................... 1 
      1.2 Free Radicals ........................................................................................... 3 
      1.3 Free Radicals in Pathophysiology ........................................................... 5 
            1.3.1 Free Radicals in Stroke .................................................................. 5 
           1.3.2 Free Radicals in Neurodegenerative diseases ................................ 6 
                     1.3.2.1 Alzheimer’s Disease ........................................................... 7 
          1.3.2.2 Parkinson’s Disease ............................................................ 8 
                     1.3.2.3 Amyotropic Lateral Scelrosis ............................................. 12 
            1.3.3 Free Radicals in Aging ................................................................... 13 
 1.4 Spin Traps ................................................................................................ 14 
 1.5 Nitrones .................................................................................................... 15 
    1.5.1 Synthesis of Nitrones ...................................................................... 19 
           1.5.1.1 Condensation of N-substituted hydroxylamine with 
                                 Aldehyde or Ketone ............................................................ 19 
             1.5.1.2 Oxidation of N-substituted hydroxyl amines ...................... 20 
             1.5.1.3 Oxidation of imines or amines ............................................ 20 
            1.5.1.4 Reductive cyclization of γ-nitro-carbony compounds ......... 21 
  1.5.2 Reactions of Nitrones ...................................................................... 21 
             1.5.2.1 1,3-dipolar cyloaddition reactions ...................................... 21 
                      1.5.2.2 Electrophilic addition reactions .......................................... 22 
             1.5.2.3 Michael and Aldol type reactions ....................................... 23 
    1.6 Edaravone ................................................................................................. 24 
      1.7 Azulenes ................................................................................................... 24 
    1.7.1 Previous work on Azulenyl Nitrones .............................................. 25 
 
 2. Research Objective ......................................................................................... 36 
      2.1 Azulenyl nitrones .................................................................................... 36 
      2.2 Pseudoazulenyl nitrones .......................................................................... 37 
 
3. Results and Discussion .................................................................................... 39 
     3.1 Synthesis of Third Generation Azulenyl Nitrones ................................... 39 
            3.1.1 Synthesis of 1-substituted bisazulenyl mononitrone ..................... 40 
      3.2 Synthesis of novel pseudoazulenyl dinitrones......................................... 43 
      3.2.1 Synthesis of 2-butyl-cyclopenta[c]pyridine-4,7-dinitrone (63) ..... 44 
     3.2.2 Synthesis of 2-(propyl imidazole)-cyclopenta[c]pyridine- 
                     4,7-dinitrone (72)............................................................................ 47 
   3.2.3 Synthesis of 2-(3-(dimentylamino)propyl)-cyclopenta[c]pyridine- 
                     4,7-dinitrone (75) ........................................................................... 50 
            3.2.4 Synthesis of Spermine analogue (86) ............................................ 51 
 
  ix 
3.2.5 Synthesis of 2-octadecylamine-cyclopenta[c]pyridine- 
         4,7-dinitrone (88) ........................................................................... 55 
   3.2.6 Synthesis of 2-(6-hexanol)-cyclopenta[c]pyridine- 
                     4,7-dinitrone (91) ........................................................................... 56 
            3.2.7 Synthesis of 2-butyl-5-ethylthio-cyclopenta[c]pyridine- 
                     4,7-dinitrone (94) ........................................................................... 57 
  3.3 Cyclic Voltammetry ................................................................................ 59 
 
4. Conclusion ...................................................................................................... 60 
 
5. Experimental section ....................................................................................... 62 
      5.0.1 Synthesis of bis-guiazulenyl monoaldehyde (49) ................................ 63 
 5.0.2 Synthesis of bis-azulenyl thio-benzothiazole-  
     monoaldehyde derivative (51) .............................................................. 66 
 5.0.3 Synthesis of thio-benzothiazole-mononitrone derivative (52) ............. 69 
 5.0.4 Synthesis of sulfenyl chloride (93) ...................................................... 72 
 5.0.5 Synthesis of 1-ethylthio bis-guiazulenyl monoaldehyde (54) ............. 72 
 5.0.6 Synthesis of 1-ethylthio bis-guiazulenyl mononitrone (55) ................. 76 
 5.0.7 Synthesis of 3-(ethylthio)-guiazulene (57) ........................................... 79 
      5.0.8 Synthesis of 3-(ethylthio)-1-carbaldehyde guiazulene (58) ................. 82 
      5.0.9 Synthesis of 3-(ethylthio)-1-nitrone-guiazulene (56) ........................... 85 
      5.1.0 Extraction of valtrate (59) .................................................................... 88 
      5.1.1 Synthesis of baldrinal (60) .................................................................... 91 
      5.1.2 Synthesis of 2-butyl-cyclopenta[c]pyridine-4,7-dicarbaldehyde (61) .. 94 
      5.1.3 Synthesis of 2-butyl-cyclopenta[c]pyridine-4,7-dinitrone (63) ............ 97 
      5.1.4 Synthesis of 5-bromo-2-butyl-cylopenta[c]pyridine- 
               4,7-dicarbaldehyde (65) ........................................................................ 100 
      5.1.5 Synthesis of 2-butyl-5-ethylthio-cyclopenta[c]pyridine- 
   4,7-dicarbaldehyde (92) ........................................................................ 103 
      5.1.6 Synthesis of 2-butyl-5-ethylthio-cyclopenta[c]pyridine- 
               4,7-dinitrone (94) .................................................................................. 105 
      5.1.7 Synthesis of 2-(propyl imidazole)-cyclopenta[c]pyridine- 
               4,7-dicarbaldehyde (71) ........................................................................ 108 
      5.1.8 Synthesis of 2-(propyl imidazole)-cyclopenta[c]pyridine- 
               4,7-dinitrone (72) .................................................................................. 110 
      5.1.9 Synthesis of 2-(3-(dimethylamino)propyl)-cyclopenta[c]pyridine- 
               4,7-dicarbaldehyde (74) ........................................................................ 113 
      5.2.0 Synthesis of 2-(3-(dimethylamino)propyl)-cyclopenta[c]pyridine- 
               4,7-dinitrone (75) .................................................................................. 115 
      5.2.1 Syntheisis of 2-octadecylamine-cyclopenta[c]pyridine- 
               4,7-dicarbaldehyde (87) ........................................................................ 118 
      5.2.2 Synthesis of 2-octadecylamine-cyclopenta[c]pyridine- 
               4,7-dinitrone (88) .................................................................................. 120 
      5.2.3 Synthesis of 2-(6-hexanol)-cyclopenta[c]pyridine- 
               4,7-dicarbaldehyde (90) ........................................................................ 123 
  x 
      5.2.4 Synthesis of 2-(6-hexanol)-cyclopenta[c]pyridine-4,7-dinitrone (91) .. 125 
      5.2.5 Synthesis of Spermine analogue of pseudoazulenyl dinitrone (86) ...... 128 
 5.2.6 Cyclic voltammetry ............................................................................... 131 
LIST OF REFERENCES ..................................................................................... 132 
 
VITA ..................................................................................................................... 148 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  xi 
LIST OF FIGURES 
 
FIGURE          PAGE 
   
 1.  Glutathione recycling ................................................................................. 11 
 
 2.  Biological fate of L-DOPA ........................................................................ 11 
 
 3.  Reactions of Nitrone and Nitroso compounds with Free Radicals ............. 14 
 
 4.  Resonance structure of Nitroso Spin Adduct ............................................. 15 
 
 5.  cis-trans isomerization of PBN .................................................................. 16 
 
 6.  Resonance structure of Nitrone .................................................................. 17 
 
 7.  Structures of PBN, S-PBN and NXY-059 .................................................. 17 
 
 8.  Structures of 3-PyBN, 4-PyOBN and 4-MePyBN ...................................... 18 
 
 9.  Structures of MDL-101,002, DMPO, DEPMPO and EMPO ..................... 19 
 
 10. Reaction of Edaravone with free radicals .................................................. 24 
 
 11. Naturally occurring azulenyl compounds .................................................. 25 
 
 12. Synthetic scheme of AZN (22) .................................................................. 26 
 
 13. Double spin adduct of AZN ...................................................................... 27 
 
 14. Reaction of AZN (22) with peroxyl radical .............................................. 27 
 
 15. One electron oxidation of Azulenyl Nitrone ............................................. 29 
 
 16. Synthetic scheme of STAZN (32) ............................................................. 32 
 
 17. Commonly used natural and synthetic antioxidants .................................. 33 
 
 18. Attempted synthesis of 1-substituted thio-benzothiazole-  
            bis-azulenyl mononitrone (53) .................................................................. 41 
 
 19. Synthetic scheme of 1-ethylthio-bis-azulenyl mononitrone (55) .............. 42 
 
 20. Synthetic scheme of 3-(ethylthio)-guiazulene-1-nitrone (56) ................... 43 
 
  xii 
 21.Synthetic scheme of Baldrinal (60) ............................................................ 44 
 
 22. Synthetic scheme of 2-butyl-cyclopenta[c]pyridine-4,7-dinitrone (63) ...  45 
 
 23. Attempted synthesis of Bis-pseudoazulenyl Tetraaldehyde (67) .............  46 
 
 24.Attemtpted synthesis of Pseudoazulenyl Dialdehyde (69) ......................... 48 
 
 25. Synthetic scheme of 2-(propyl imidazole)- 
       cyclopenta[c]pyridine-4,7-dinitrone (72) .................................................. 49 
 
 26. Synthetic scheme of 2-(3-(dimethylamino)propyl-        
            4,7-cyclopenta[c]pyridine-dinitrone (75) .................................................. 50 
 
 27. Trypanothione ............................................................................................ 52 
 
 28. Attempted synthesis of Spermine derivative of pseudoazulenyl  
           dialdehyde (80) ........................................................................................... 53 
 
 29. Attempted synthesis of piperazine derivative of pseudoazulenyl  
            dinitrone (81) ............................................................................................. 54 
 
 30. Synthetic scheme of dicationic spermine analogue of  
             pseudoazulenyl dinitrone (86) .................................................................. 55 
 
 31. Synthetic scheme of 2-octadecyl-cyclopenta[c]pyridine- 
       4,7-dinitrone (88) ........................................................................................ 56 
 
 32. Synthetic scheme of 2-(6-hexanol)-cyclopenta[c]pyridine- 
            4,7-dinitrone (91) ........................................................................................ 57 
 
 33. Synthetic scheme of 2-butyl-5-(ethylthio)-cyclopenta[c]pyridine- 
            4,7-dinitrone (94) ........................................................................................ 58 
 
 34. Cyclic voltammogram of 2-butyl-5-ethylthio-cyclopenta[c]pyridine- 
            4,7-dinitrone (94) ........................................................................................ 59 
 
 35. Cyclic voltammogram of STAZN (32) ....................................................... 60 
 
  1 
[1] INTRODUCTION 
[1.1] History: 
Commoner et al. first discovered free radicals in biological systems in 1954.1 
Soon after this discovery, Harman proposed his “Free Radical Theory of Aging” in which 
free radical damage was putatively attributed to mutagenesis, cancer and degenerative 
diseases of aging.2 Harman’s theory attracted criticism since most of the scientists at that 
time believed that free radicals were too reactive to exist in biological system. McCord 
and Fridovich (1969) isolated superoxide dismutase (SOD) and showed that this enzyme 
was capable of preventing the oxidation of substances against the superoxide radical  
(O2•–), suggesting SOD plays a vital role in protecting organisms against the damaging 
superoxide radical by accelerating dismutation of superoxide radical (O2•−) to oxygen and 
hydrogen peroxide (H2O2).3 
2O2 + 2H
+ H2O2
+ O2
SOD [1]
 
The discovery of SOD, whose sole function in physiology is to eliminate harmful reactive 
oxygen species (ROS), proved pivotal to the understanding of the role of free radicals in 
physiology. Researchers have shown that transgenic mice lacking this enzyme die soon 
after birth signifying the biological importance of SOD.4,5 Biological macromolecules 
such as lipids, nucleic acids and proteins are the targets of endogenous free radicals. For 
example, hydroxyl radicals can rapidly cause oxidation of DNA bases, particularly 
guanines. It can also attack lipids and proteins to give lipid peroxidation products and 
carbonyls, respectively.6 
However, the toxicity of the superoxide radical is not limited to its reaction with 
biomolecules alone. Superoxide  (O2•–) is shown to react with other ROS and free radicals 
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to produce even more harmful species. One such reaction is the Haber-Weiss reaction, 
where in the presence of a catalytic amount of ferric ion, superoxide reacts with hydrogen 
peroxide to give a hydroxyl radical.7 
O2 + H2O2 OH
+ OH + O2
Fe3+ + O2 Fe2+ + O2
Fe2+ + H2O2 Fe
3+ + OH OH+
2
3
Net 
Reaction 
   [4]  
Mittal and Murard (1977) published on the biological significance of free 
radicals.8 They suggested that the superoxide ion and hydrogen peroxide can lead to 
formation of hydroxyl radicals that activate guanylate cyclase which catalyzed the 
formation of the “second messenger” 3',5'-cyclic guanosine monophosphate (cGMP) 
from guanosine triphosphate (GTP). Free radicals were shown to be generated by 
phagocytes in defense against microorganisms.9,10 Individuals with chronic 
granulomatous disease were shown to have abnormal susceptibility to infectious 
organisms because of a lack of NADPH oxidase, which reduces oxygen to the superoxide 
radical anion.11 Furthermore, free radicals are also important in apoptosis.12 The 
paradoxical role of free radicals triggered extensive research in this field, with ongoing 
debate on the advantageous and deleterious effects of free radicals. 
 Even though free radicals play a vital role in signal transduction and defense 
mechanisms, collateral damage is inevitable. Excessive production of free radicals can 
lead to various pathological conditions with differing severity. Free radicals have been 
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implicated in various disease conditions like hypertension and atherosclerosis,13-15 
rheumatoid arthritis,16,17 cancer,18-21 diabetes,22,23 and aging,2,24-26 as well as degenerative 
diseases like amyotrophic lateral sclerosis (ALS),27 Alzheimer’s disease,28-30 Down’s 
syndrome,31, 32 and bovine spongiform encephalopathy.33 
 
[1.2] Free Radicals: 
The most oxidizing species in physiology is the hydroxyl (⋅OH) radical having an 
extremely short half-life of 10-9s.34 However, the most ubiquitous free radical in 
physiology is the NO⋅ radical. It is a lot less reactive than the ⋅OH radical. Even though 
NO⋅ is less reactive with other biomolecules, it is still extremely reactive with other free 
radicals. For example, NO⋅ can react with O2•− to give peroxynitrite, ONOO−,35, 36 
NO + O2
ONOO [5]  
Decomposition of ONOO   leads to the formation of highly reactive hydroxyl (⋅OH) 
radical, via the intermediacy of ONOOH which itself is highly reactive.37  
ONOOH OH
+ NO2 [7]
ONOO + H+ ONOOH [6]
 
NO⋅  also reacts with hydroxyl and peroxyl radicals to give nitrous acid and 
peroxynitrites, respectively. 
NO + OH HNO2 [8]  
 
NO + RO2 ROONO [9]  
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Superoxide dismutase (SOD) prevents the excessive formation of ONOO- by 
removing harmful O2•− radicals, thereby limiting the formation of •OH.38 Another 
common way of ROS generation in physiology is by Fenton reaction. In 1894, H.J.H. 
Fenton observed that H2O2 and ferrous or ferric ions react together to form hydroxyl and 
hydroperoxyl radicals, respectively.  
Fe2+ + H2O2 Fe
3+ + OH + OH
Fe3+ + H2O2 Fe
2+ + + H+OOH
[10]
[11]  
The presence of iron in this reaction is truly catalytic. Note that, the Fenton reaction is 
also the second step in the Haber-Weiss reaction. Similarly, other metal ions like copper 
(I) react with hydrogen peroxide in much the same way as iron but with a greater rate 
constant.  
Cu+ + H2O2 Cu
2+ + OH + OH [12]  
Iron is abundantly available in the body. Fortunately, very little is available as free iron. 
An average adult body contains approximately 4 grams of iron, most of which is present 
in hemoglobin (~ 60%). The other major sources of iron are myoglobin, transferrin, 
ferritin and haemosiderin.39 Whereas for copper, approximately 95% of this metal ion is 
found in the protein caeruloplasmin with a small amount in albumin and plasma amino 
acids. 
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[1.3] Free Radicals in Pathophysiology: 
[1.3.1] Free Radicals in Stroke: 
 According to the National Stroke Association, stroke is the third leading cause of 
death in America and a leading cause of adult disability. An ischemic stroke results due 
to acute interruption or reduction of blood flow to the brain caused by thrombosis or 
embolism of one of the main cerebral arteries, causing hypoxia that can result in either 
transitory or permanent damage to the brain. Agents that lyse these clots are called 
thrombolytics such as tissue plasminogen activator (tPA), which reperfuse the brain. 
Currently, tPA is the only agent approved by the U.S. Food and Drug Administration 
(FDA) for stroke resulting due to thrombosis. Another less common cause of stroke is 
cardiac arrest. 
During the early 1970s, research increasingly suggested that free radicals might 
be responsible for neuronal damage and cell death in the brain.40 Studies showed that free 
radical-mediated oxidative stress may damage the mitochondrial membrane because of 
the presence of a high level of oxidatively sensitive polyunsaturated fatty acids.40,41 Later, 
increased production of free radicals in the ischemic brain was demonstrated, and there is 
ample evidence to show that reperfusion of ischemic brain worsens the oxidative stress 
by producing highly reactive superoxide and hydroxyl radicals.42-44 Generation of ROS in 
reperfused ischemic brain was postulated to be due to the release of metal ions from 
injured cells.45 This increased production of ROS is especially harmful to the nervous 
system since levels of endogenous antioxidants are low during such pathological 
conditions. Examples of endogenous antioxidants are- (a) antioxidant enzymes such as 
superoxide dismutase (SOD), catalase, glutathione reductase (GR) and glutathione 
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peroxidase (GPO); (b) antioxidant vitamins such as vitamin E (α-tocopherol), and 
ascorbic acid.46 Deficiency of endogenous antioxidant enzymes results in increased 
neuronal damage in focal cerebral ischemia,47 whereas over expression of these enzymes 
has been shown to increase resistance to focal cerebral ischemic injury.48,49 
In a stroke, many of the compounds investigated until now act early during the 
ischemic cascade (glutamate antagonists, ion channel antagonists, GABA mimetics, 
thrombolytics, etc.), thereby limiting the duration of the therapeutic window when these 
drugs could be administered.50 Therefore, to be effective, these compounds should be 
administered very soon after the stroke. Tissue plasminogen activator (tPA), which is 
currently recommended for acute ischemic stroke therapy, has a very short therapeutic 
window (3 h), thereby limiting its utility. Another approach suggested by Green et al. is 
to develop drugs that are effective during the late ischemic cascade in hopes that they will 
have a longer therapeutic window with nitrones suggested as effective candidates.50  
 
[1.3.2] Free Radicals in Neurodegenerative diseases: 
 Neurodegenerative diseases are a heterogeneous group of diseases of various 
parts of the Central Nervous System (CNS), which include the brain, the spinal cord and 
the peripheral nervous system. All human tissues, directly or indirectly, are affected by 
oxidative damage. However, the brain and the nervous system are especially susceptible 
because of the presence of high amounts of unsaturated fatty acids and iron.51 Even 
though the brain comprises a small percentage of all tissue mass, it is still the most 
oxygenated mass in the body. The brain consumes about 20% of basal oxygen in the 
body because of the high oxygen demand by the cerebral mitochondria to keep up with 
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ATP requirements for normal neuronal functioning. Mitochondria are both generators 
and targets of free radicals. Increased oxidative stress damages mitochondria, which in 
turn affects the normal neuronal functions since neurons need a constant supply of ATP 
to function properly. Damaged mitochondria produce more reactive species, which in 
turn damages more mitochondria, resulting in a vicious cycle eventually causing cell 
degeneration and apoptosis. The common neurodegenerative diseases are discussed here. 
 
[1.3.2.1] Alzheimer’s Disease: 
 Alzheimer’s disease (AD) is a common form of dementia with impairment of 
cognitive function and personality. Alzheimer’s disease is characterized by neuronal 
degeneration of pyramidal neurons in the hippocampus, entorhinal cortex and neocortical 
areas, and by loss of cholinergic neurons in the median forebrain.52,53 Alzheimer’s disease 
is thought to occur due to accumulation of neurofibrillary tangles, which consists of 
hyperphosphorylated tau protein and amyloid plaques of amyloid β (Aβ) protein, 
resulting in extensive neuronal loss in the brains of Alzheimer’s patients. The major 
component of plaques in AD is the 40-42 amino acid, amyloid β protein, which is a 
segment from the larger Amyloid β protein precursor (βAPP) and result due to alterations 
in the metabolism of βAPP.54,55 The finding that the amyloid β protein is toxic to neurons 
in vitro led to the hypothesis that amyloid β protein plays a role in neuronal degeneration 
in AD.56 The toxicity of Aβ protein is thought by some to be due to its ability to form 
insoluble aggregates which lead to increased production of reactive oxygen species 
(ROS),57 loss of calcium homeostasis,58  and eventual cell degeneration and apoptosis. 
However, the reverse has also been implicated in that the toxicity of Aβ protein has been 
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speculated by some to be due to its action as an oxidant.59 Such toxic effects of 
aggregates of Amyloid β peptide were later shown by other researchers, supporting 
earlier data.56,60,61 Furthermore, Aβ protein was also shown to induce lipid peroxidation 
in synaptosomes and cultured cortical cells.62,63  
 Further studies have demonstrated that oxidants promote and antioxidants prevent 
aggregation of Aβ.64 Yan et al. suggested that β-amyloid peptides cause neurotoxic 
effects, directly by inducing oxidative stress and indirectly by activating microglia,65 
which were shown to be the major source of free radicals when activated.65,66  However, 
under normal circumstances, secretion of ROS by microglia is a defense mechanism to 
protect the brain against invading pathogens.66 Further evidence for the production of 
ROS by glial cells came from the fact that in response to injury, glial cells undergoes 
gliosis (overgrowth of glial cells/astrocytes). Halks-Miller et al. proposed that when 
activated, glial cells secrete free radicals and undergo gliosis, which can be prevented by 
α-tocopherol (vitamin E).67 Smith et al. correlated Alzheimer’s with aging by stating 
that AD is an alteration in normal aging processes in the brain areas that are challenged 
by increased oxidation with increased age.68 
 
 [1.3.2.2] Parkinson’s Disease:  
  Parkinson’s disease (PD) is the most common neurodegenerative movement 
disorder and was first described by James Parkinson in 1817. Parkinson’s disease 
involves neurodegeneration of melanin-pigmented dopaminergic neuron of the 
substantia nigra pars compacta (SNpc) of the midbrain. Parkinson’s disease is 
manifested by declining motor and cognitive functions, and depression.69 The exact 
  9 
cause of dopaminergic cell loss is still obscure. However, recent research has shown that 
oxidative stress is one of the main reasons for neuronal death leading to PD.70,71 It has 
also been established that mitochondrial function in a PD brain is impaired, especially 
the complex I of the mitochondrial electron transport chain.72,73  Most of this evidence 
comes from studies done on the neurotoxin 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) which gets converted to its active metabolite 1-methyl-4-
phenylpyridinium (MPP+) by monoamine oxidase B.74 MPTP causes PD syndrome, 
which is indistinguishable from idiopathic PD and thus supports the theory of toxic 
causation. MPP+ accumulates rapidly in dopaminergic neurons and inhibits complex I of 
the mitochondrial electron transport chain. Inhibition of mitochondrial electron transport 
chain leads to impairment of energy production and eventually leads to the death of 
dopaminergic neuronal cells. There is substantial evidence that MPP+ increases 
oxidative stress in the brain and antioxidants tend to attenuate the effects of MPTP 
toxicity.75,76 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is often used as an 
animal model of Parkinson’s disease.  
 It has also been shown that dopamine undergoes oxidation by monoamine oxidase 
to form H2O277 with a subsequent increase in oxidized glutathione (GSSG), incriminating 
oxidative stress and impairment of major antioxidant systems in PD.78 Increased levels of 
iron in the substantia nigra has also been implicated in PD79-81 which can lead to Fenton 
reaction between iron and H2O2 to form highly toxic hydroxyl radicals (•OH) that may 
then initiate lipid peroxidation and cell death.82-84 It was also postulated that the reactions 
involving H2O2, iron and dopamine may be responsible for the formation of 
dopaminergic neurotoxins such as 6-hydroxydopamine.85-87 Because of constant 
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oxidative bombardment, the brain is also exceptionally well-equipped with antioxidant 
defense mechanisms with various antioxidants like α-tocopherol, glutathione, ascorbic 
acid, ubiquinol, carotenoids, and flavanoids, as well as antioxidant enzyme systems such 
as catalase, superoxide dismutase (SOD), glutathione-S-transferase, glutathione 
reductase, and thioredoxin reductase.88 Glutathione plays an important role in protecting 
the brain against reactive oxidative species. In PD, decreased levels of GSH have been 
observed. A decreased level of total glutathione (GSH+GSSG) is one of the first 
biochemical indicators in PD brain, appearing even before the decreased activity of 
mitochondrial complex I. It has been established that the magnitude of GSH depletion 
parallels the severity of PD making it an excellent biomarker.89,90 
 Nitric oxide reacts with the hydrogen peroxide (H2O2) to form peroxynitrite 
(ONOO-), which is not only a strong oxidizing agent but also degrades to an even more 
powerful hydroxyl radical (•OH).91 Nitric oxide is responsible for reversible and 
irreversible damage to mitochondrial respiratory complex I and IV.92 Furthermore, NO 
may also affect GSH levels by selectively inhibiting GSH reductase which is crucial for 
the conversion of oxidized glutathione (GSSG) back to its reduced form, GSH.93 In 
normal physiology, GSH and GSSG are in the ratio of 98:2 and are interconvertible by 
the action of two enzymes, glutathione peroxidase (GSH-Px) and glutathione reductase 
(GSSG-R).  
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GSH GSSG
GSH peroxidase
GSSG reductase
H2O2 H2O
NADPH, H+NADP+
Figure 1. Glutathione recycling  
  
 The most frequently prescribed drug for PD is Levodopa (L-DOPA), which acts 
as a prodrug and gets converted to dopamine by DOPA decarboxylase in the CNS.  
 
NH2HO
HO
dopamine
HO
HO
NH2
O
OH DOPA decarboxylase
L-DOPA
Figure 2. Biological fate of L-DOPA  
 
Levodopa is preferred over dopamine because of its ease in crossing the blood brain 
barrier (BBB). However, levodopa is easily inactivated peripherally by DOPA 
decarboxylase. Therefore, levodopa is usually combined with DOPA decarboxylase 
inhibitors such as carbidopa or benserazid, to prevent peripheral levodopa degradation. 
However, this treatment suffers from some major drawbacks. Levodopa and dopamine 
are both found to undergo autoxidation under physiological conditions to give cytotoxic 
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reactive oxygen species.94 Furthermore, they only provide symptomatic relief and 
patients develop tolerance over time. Therefore increased doses are needed which in turn 
increases the severity of side effects.95 
 
[1.3.2.3] Amyotrophic Lateral Sclerosis: 
 Amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s disease is an age dependant 
motor neuron degenerative disease and occurs in the 5th or 6th decade of life.96 
Amyotrophic lateral sclerosis is characterized by progressive loss of motor neurons in the 
motor cortex, the brain stem and the spinal cord, that affect motor functions and is 
followed by progressive muscle atrophy.97 Certain familial Amyotrophic lateral sclerosis 
cases have been linked to a genetic defect in chromosome 21, in the gene encoding 
CuZnSOD protein.98 However, the mechanism behind this gene alteration is still 
uncertain. These mutant CuZnSOD have been linked to the pathogenesis of ALS due to 
alteration in the functions of SOD. Approximately 20% of familial ALS cases have been 
attributed to such mutations.99 Lee et al. have shown that the cell cultures overexpressing 
normal CuZnSOD are more resistant to oxidative stress, serum deprivation, addition of 
H2O2, and 4-hydroxynonenal (cytotoxic unsaturated end product of lipid peroxidation). 
On the other hand, cell cultures over expressing mutant CuZnSOD were found to be 
extremely vulnerable to such insults.100 Even though the exact mechanism of the toxicity 
of mutant CuZnSOD is poorly understood, it was found that mutant CuZnSOD is less 
stable in vitro and may therefore denature more quickly than normal CuZnSOD, thus 
releasing copper and zinc metal101, 102 which are known to act as a catalyst to increase 
oxidative stress in physiology.101, 103 
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[1.3.3] Free Radicals in Aging:  
It has been almost 60 years since the free radical theory of aging was proposed by 
Harman.2 Since the inception of this theory, an enormous amount of data has 
accumulated over the years in support of this theory. Mice carrying a targeted mutation of 
the p66Shc gene have shown prolonged life spans with about 30% more than control 
mice104 and also exhibited increased resistance to oxidative stress and decreased 
production of intracellular oxidants.105,106 Hazelton et al. showed that glutathione 
concentration decreases during aging.107 In animal models, up to 20-30% decreases in 
GSH levels were observed in liver, kidney and heart; however, they suggested that 
decreases in GSH levels are not restricted to a particular tissue but occur in all aging 
tissue. Even though GSSG levels were almost unaltered, it was suggested that the 
GSH/GSSG ratio is critical in aging. Furthermore, a reduced capacity to detoxify free 
radicals and xenobiotics due to reduced GSH levels was suggested to be the toxicological 
basis of aging.107 In a study done on community-based elderly, good health and fewer 
illness were associated with higher levels of GSH, whereas subjects associated with 
illnesses such as arthritis, diabetes, and heart disease were found to possess lower levels 
of GSH.108,109 Furthermore, decreased levels of GSH are also associated with impairment 
of mitochondrial functions. When cells were exposed to mitochondrial poisons like 
Antimycin A, KCN, and/or 1-methyl-4-phenylpyridinium ion (MPP+), these compounds 
were shown to produce a marked decrease in GSH levels. This decrease in GSH levels 
was proposed to be a result of the loss of ATP production in mitochondrial poisoning.110 
When GSH in rat brain was depleted by L-buthionine sulfoximine, mitochondrial 
function was reported to be decreased by 27%.111 
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[1.4] Spin Traps:  
 Direct detection of most free radicals is exceedingly difficult due their extremely 
short half-life. Therefore, the technique of spin trapping is usually employed where these 
short-lived free radicals are trapped with nitrones or nitroso compounds to give spin 
adducts  (nitroxides) which are considerably more stable than the parent free radical. The 
structure or identity of free radicals can in some cases be identified using the Electron 
Spin Resonance (ESR) [also called as Electron Paramagnetic Resonance (EPR)] 
technique based on the signature spectrum that these molecules produce.  
 The compounds that trap the free radicals are called spin traps. Janzen coined the 
term “spin trapping” due to similarities between the processes of spin labeling and spin 
trapping.112 The addition product of a free radical and a spin trap is called a “spin 
adduct”.113  
R + Spin Trap Spin Adduct  
As stated above, the two most commonly used free radical traps are nitrones and nitroso 
compounds. Their reactions with free radicals to yield nitroxides are shown in the figure 
below.  
N O + R N
O
R
t-Nitrosobutane
Nitroso spin adduct
CH
N
O
+ R
CH
N
O
R
PBN Nitrone spin adduct
Figure 3. Reactions of Nitrone and Nitroso compounds with Free Radicals  
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The stability of these spin adducts are due to resonance delocalization of the unpaired 
electron. 
N
O
R
Nitroso spin adduct
N
O
R
Figure 4. Resonance structure of Nitroso Spin Adduct
 
In spin adducts resulting from nitroso compounds, the free radicals became attached 
directly to the nitrogen therefore giving additional hyperfine coupling that could in 
principle make the identification of free radicals easier than that resulting from nitrone 
spin traps. However, despite this obvious advantage, the use of nitroso compounds as 
spin traps suffers from various drawbacks. Thus, nitroso compounds are toxic, thermally 
and photochemically unstable, and the lifetime of their oxygen-centered radical adducts 
are exceedingly short.114 For these reasons, researchers prefer nitrones over nitroso 
compounds, especially in biological systems, despite the fact that the EPR spectra of their 
nitroxide spin adducts provide less structural information. 
 
[1.5] Nitrones: 
Nitrones are the N-oxide of an imine represented by the general formula as shown in (1). 
Pfeiffer in 1916 coined the term "nitrone" considering the similarity of the NO group in 
nitrones to the C=O group in ketones.115 
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R1
R2
N
O
R3
(1)  
 
 An early review on nitrones and structural analogues states that it is not the nitrogen-
oxygen bond that behaves as a carbonyl, but the entire nitrone moiety as shown in (1).116 
It has been proved by nuclear magnetic resonance (NMR) and infrared (IR) studies that 
aldonitrones possess a stable trans geometry.117 Cis-PBN was shown to isomerize 
completely to trans-PBN in benzene solution within 24 h. 
 
N N
H
O
H O
trans-PBN cis-PBN
Figure 5. cis-trans isomerization of PBN  
 
Nitrones can be written in two resonance forms, with major contribution from form I.118 
Because of these resonance structures, nitrones behave as 1,3-dipolar compounds and 
undergo reactions typical for this group of compounds, i.e., 1,3-dipolar cycloaddition 
reactions. 
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N
R
H R'
O
N
R
H R'
O
I II
Figure 6. Resonance structure of Nitrone
 
 
An archetypal representative from the nitrone class of compounds is α-phenyl-N-
tert-butyl nitrone (α-PBN) (2). α-phenyl-N-tert-butyl nitrone is the most extensively 
studied nitrone. It reacts, albeit not always efficiently, with short-lived free radicals such 
as superoxide, alkoxyl and hydroxyl radicals and forms a stable nitroxide (Figure 3), 
thereby, in some cases, neutralizing these harmful free radicals and removing them from 
circulation. α-phenyl-N-tert-butyl nitrone (PBN), at relatively high concentration, also 
has the ability to prevent oxidation of lipids like low-density lipoprotein.119 Although, 
various derivatives of PBN have been synthesized, the most extensively studied 
derivatives in vivo are S-PBN (3) and NXY-059 (4).  
 
N
O
N
O
SO3Na
N
O
SO3Na
NaO3S
PBN (2) S-PBN (3) NXY-059 (4)
Figure 7. Structures of PBN, S-PBN and NXY-059  
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Comparison of the activity of PBN, S-PBN and NXY-059 with free radicals showed that 
the nitroxides resulting from NXY-059 are the most stable.120 Recently, AstraZeneca 
stopped development of NXY-059 drug for acute stroke after failure of phase IIIb clinical 
trials. However, NXY-059 was reported to show promising results in Phase II and Phase 
IIIa clinical trials. Various reasons have been hypothesized for the failure of NXY-059 
such as variable concentration of tert-butylhydroxylamine as an active hydrolysis product 
in older batches and NXY-059’s low blood brain barrier permeability.121, 122 
Various other derivatives of PBN have been synthesized in order to improve spin-
trapping physicochemical properties, like 3PyBN (N-tert-butyl-α-(3-pyridyl)nitrone) 
(5),123 4-PyOBN (α-pyridyl-1-oxide N-tert-butyl nitrones) (6),124 and 4-MePyBN (4-(N-
methylpyridinium)-t-butyl nitrone) (7).125  
N
N
O
O
4-PyOBN (6)
N
N
O
4-MePyBN (7)
N
N
O
3-PyBN (5)
Figure 8.  Structures of 3-PyBN, 4-PyOBN and 4-MePyBN  
MDL-101,002 (8) is a cyclic variant of PBN, synthesized with the purpose to increase the 
potency of PBN. Fixing the t-butyl group to the back exposes the nitrone functionality 
making it a more potent spin trap than PBN. Other cyclic variants of nitrones like DMPO 
(5,5-dimethyl-1-pyrroline-N-oxide) (9),126 DEPMPO (2-diethoxyphosphoryl-2-methyl-
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3,4-dihydro-2H-pyrrole-1-oxide) (10),127 and EMPO (5-ethoxycarbonyl-5-methyl-
pyrroline N-oxide) (11)128 were also synthesized.  
 
N
O
MDL-101,002 (8) EMPO (11)
N
H
O
DMPO (9)
N
(OEt)2(O)P
O
DEPMPO (10)
N
EtO2C
O
Figure 9. Structures of MDL-101,002, DMPO, DEPMPO, and EMPO  
 
[1.5.1] Synthesis of Nitrones: 
 Some important and common routes to synthesize nitrones are discussed in this 
section. 
 
[1.5.1.1] Condensation of N-substituted hydroxylamine with Aldehyde or Ketone: 
The most common method to synthesize a nitrone is by condensation of N-
substituted hydroxylamines with an aldehyde or a ketone as shown in the scheme 
below.129, 130 This reaction usually gives a very good yield, especially with unhindered 
aldehydes and ketones. 
R R'(H)
O
+
N
R''
HO H
R R'(H)
N
R'' O
Aldehyde/Ketone Hydroxylamine Nitrone  
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[1.5.1.2] Oxidation of N-substituted hydroxyl amines:  
Nitrones can be readily prepared by oxidation of corresponding N,N-disubstituted 
hydroxylamines. Oxidation can be achieved by a variety of oxidizing agents such as 
yellow mercuric oxide,131 potassium permanganate, lead oxide,132 air oxidation133 and 
hydrogen peroxide.134 These methods are particularly useful for the synthesis of cyclic 
nitrones. 
N
OH
CH
RR''
R'
N
O
C
RR''
R'
O
 
 
[1.5.1.3] Oxidation of imines or amines:  
MDL 101,002 was synthesized by oxidation of an imine.135 This reaction suffers 
from the drawback of long reaction times (7 days) and multiple additions of oxidants. By 
reducing imines to amines and then oxidizing the amines to nitrones, one can eliminate 
both of these drawbacks and obtain a cleaner reaction.136, 137 
 
N N
O
H2O2/H2O/EtOH
cat. Na2WO4
NH
NaBH4
H2O2/H2O/EtOH
cat. Na2WO4
MDL-101,002 (8)
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[1.5.1.4] Reductive cyclization of γ-nitro-carbonyl compounds:  
The reduction of γ-nitro-carbonyl compounds with zinc dust and ammonium 
chloride gives cyclic nitrones.138 Various derivates of DMPO were synthesized via this 
route.  
 
O
NO2
Zn/NH4Cl
N
O
DMPO  
[1.5.2] Reactions of Nitrones: 
[1.5.2.1] 1,3-dipolar cycloaddition reactions: 
Nitrones undergo 1,3-dipolar cycloaddition reactions with alkenes (3+2) to give 
isoxazolidines in much the same way as the classical (4+2) Diels-Alder reaction.118,139,140 
Isoxazolidines are used as precursor in the synthesis of many natural products such as 
alkaloids.139  
N
OR
R1 R
2 R5 R6
R4R
3
N
O
R
R2
R1
R5
R6
R3
R4
+ Enantiomers
Nitrone Alkene isoxazolidine  
Analogously, nitrones were also shown to undergo cycloaddition reactions with various 
substituted alkynes.141  
  22 
N
O
+
H3COOC
O
R
N
O
H3COOC
R  
[1.5.2.2] Electrophilic addition reactions: 
 Nitrones possess one of the most polarized C=N bonds, giving them the ability to 
undergo metal catalyzed electrophilic addition reactions. Nitrones were shown to undergo 
addition reactions with organomagnesium or organolithium compounds to give N,N-
disubstituted hydroxylamines which can be easily reduced to secondary amines. This 
reaction is often used as an alternative to the addition of organometallic reagents to C=N 
bonds of imines or imine derivatives such as hydrazones and oximes.  
N
R1
H R2
O
R3MgX
R3Lior
N
R1
R3 R2
OH
Reduction
NH
R1
R3 R2  
 
Furthermore, nitrones contain a highly reactive electronegative oxygen, which can 
chelate strongly with metal ions and chiral auxiliaries to provide control over the 
setreoselectivity of addition.142 
N
H
Ph
O
Ph
O
NPh
OH
Ph
O
+
NPh
OH
Ph
O
MeMgBr
95 : 5  
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The proposed chelated transition state involved in these reactions is shown below.142 
N
H
Ph
O
Ph
O
Mg
Transition state  
 
[1.5.2.3] Michael and Aldol type reactions: 
Cyclic as well as acyclic nitrones readily undergo deprotonation to furnish the 
corresponding resonance-stabilized carbanions, which undergo Michael type and aldol 
type reactions.143 
N
N
O
CH2
O N N
OHO  
 
N
O
CH2
H O
N
O  
 
Because of the flexibilities offered by the nitrone functionality, many total syntheses 
employ nitrone intermdediates. 
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[1.6] Edaravone: 
 Edaravone (MCI-186) (12), although not a nitrone, is an efficient antioxidative 
radical scavenging agent. It is the only agent from this category in clinical practice in 
Japan for acute ischemic stroke.144 Edaravone enolate (13) is reported to be the active 
form in scavenging free radicals by one electron transfer. It is also effective in acute 
myocardial infarction.145 Edaravone was shown to be effective in quenching the hydroxyl 
radical (OH) and inhibiting both OH-dependent and OH-independent lipid 
peroxidation. The biological fate of edaravone is shown in figure 10. 
 
N
N
O
Edaravone (12)
N
N
O
Edaravone enolate (13)
N
H
N
O
O2
OPB (16)
[2-oxo-3-(phenylhydrazono)-butanoic acid]
N
N
O
O
N
HN
COOHOH2O
(14)
(15)
LOO
HO
LOO
HO
Figure 10. Reaction of Edaravone with free radicals  
 
[1.7] Azulenes: 
 Azulenes are non-benzenoid bicyclic aromatic compounds. The parent compound 
from this class is azulene (17), which is a deep blue-colored solid. Azulene hydrocarbons 
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are obtained from natural sources. For example, guiazulene (18) is obtained from the 
wood of Guaiacum officinale, from patchoule oil of Pogostemon pathouli, and from 
eucalyptus oil of Eucalyptus globulus; chamazulene (19) is obtained from camomile oil 
of Matricaria camimilla, from oil of yarrow Achillea millefoum, and from oil of 
wormwood Artemisia absinthium; lactaroviolin (20) is obtained from edible fungi 146 and 
vetivazulene (21) from vetiver oil. Azulenes were shown to have therapeutic properties, 
for example, guiazulene itself was shown to exhibit anti-inflammatory and antioxidant 
properties.147  
 
Azulene (17) Guiazulene (18) Chamazulene (19)
Vetivazulene (21)
O
Lactaroviolin (20)
Figure 11. Naturally occuring azulenyl compounds  
 
[1.7.1] Previous work on Azulenyl Nitrones: 
 In 1995, Becker reported the synthesis of a novel azulenyl nitrone AZN (22) in 
three efficient steps from the readily available sesquiterpene, guiazulene (18).148  
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Guiazulene (18)
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(2) EtOH
DDQ
O OEt
O
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N
H
AZN (22)
(23) AZA (24)
Figure 12. Synthetic scheme of AZN (22)  
 
This first publication on azulenyl nitrones focused on spin trapping with colorimetric 
detection, since AZN yields characteristically colored and highly visible diamagnetic 
(and paramagnetic) spin adducts. 
Therefore, when emerald green azulenyl nitrone (22) was treated with an azo-compound 
(23) in toluene at 95ㅇC, the violet colored double spin adduct (24) was formed.  
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O
OEtN
O
Azulenyl Nitrone (22)
N
CN
N
CN
(23)
O
OEtN
O
Azulenyl Nitrone (24)
NC
NC
H
H
Emerald Green
Violet
Figure 13. Double spin adduct of AZN  
This colorimetric detection of free radicals is highly convenient and was extended to 
biological systems. It was shown that AZN upon trapping peroxyl radical gives nitroxide 
(25), which undergoes fragmentations to give azulenyl aldehyde (26).  
O
OEtN
O
Azulenyl Nitrone (22)
H
Emerald Green
O
OEtN
O
ROO
O
OEtO
+ N
O
RO
Nitroxide (25)
 Purpule
Aldehyde (26)
Red
Akloxy alkyl nitroxide
ROO
Figure 14. Reaction of AZN (22) with peroxyl radical  
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Aldehyde (26) can be easily detected by analytical techniques such as UV/VIS 
colorimetric detection. The formation of this aldehyde was shown to be an excellent 
indicator of oxidative stress in brain ischemia/reperfusion in gerbil models.149 and in a 
transgenic mouse model of ALS.183 
The oxidation potential of azulenyl nitrone (22) was found to be 0.84 V vs SCE, 
which was considerably lower than previously reported nitrones. Unlike conventional 
nitrones such as PBN (2) and S-PBN (3), oxidation of azulenyl nitrones are chemically 
and electrochemically fully reversible.75,150 For the first time, the oxidation potential of a 
nitrone based spin trap was reported to be close to that of the oxidation potentials of 
important biological antioxidants such as glutathione (Ep=0.69V) and β-carotene 
(Ep=0.76V). Previous studies to correlate oxidation potential with free radical scavenging 
ability have shown that antioxidants possessing efficient free radical scavenging ability 
have significantly low oxidation potentials.151 Oxidation potentials of some nitrones are 
given in Table 1. 
Table 1. Oxidation Potential of various nitrones 
Nitrones Oxidation Potential 
in V 
PBN (2) 1.47 
2-S-PBN (3) 1.34 
4-PyBN (5) 1.93 
3-PyBN  1.67 
3-PyOBN (6) 1.84 
4-PyOBN 1.37 
DMPO (9) 1.63 
4-MePyBN (7) 2.32 
3-MePyBN 2.10 
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Furthermore, direct correlation of oxidation potential from this list can be drawn such 
that, electron-withdrawing groups are seen to increase the oxidation potential, thus 
making it difficult for nitrones to lose an electron to an oxidizing species.152 
The unusually low oxidation potential of an azulenyl nitrone was attributed to the 
formation of the resonance stabilized radical cation as an α,β-unsaturated aminoxyl (27) 
in addition to the presence of the aromatic tropylium cation (28). 
 
N
R2
R1
O
N
R2
R1
O
N
R2
R1
O
-e
(27) (28)
Figure 15. One electron oxidation of Azulenyl Nitrone  
 
Another water soluble azulenyl derivative, azulenyl bis-nitrones (w-AZN)(29) was shown 
to have even lower oxidation potential of 0.63 V vs. SCE.153  
N
H
O
H
N
O
W-AZN (29)  
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Evaluation of the pharmacological activity of AZN (22) and W-AZN (29) against 
oxidative stress has shown that azulenyl nitrones are excellent therapeutic candidates in 
free radical-mediated pathological conditions.75 Pharmacological evaluation of these first 
generation azulenyl nitrones has shown that they protect the brain against MPTP-induced 
neurotoxicity in Parkinsonism.75 Both lipid soluble AZN and water-soluble W-AZN 
provided dose dependent protection against dopamine depletion and homovanillic acid 
depletion. It was also shown that the number of dying axotomized ganglion cells in the 
developing chick retina can be reduced by administration of AZN alone or in 
combination with N-acetyl cysteine (NAC).154 The combination of azulenyl nitrone and 
NAC has a synergistic effect, which is in contrast to the antagonistic effect shown by the 
combination of PBN and NAC.  In a competition experiment performed to determine the 
efficacy of AZN in spin trapping as compared to PBN (3), AZN turned out to be 50% 
more effective as PBN in trapping free radicals.150 This increased potential of azulenyl 
nitrone to trap free radicals has been attributed to its low oxidation potential. 
 In 1964, Hünig et al. correctly assigned the structure of the remarkably stable 
hydrocarbon radical cation (31).155 In methylene chloride, a 10-5 M solution of compound 
(31) showed remarkable stability and a 2.5 x 10-2 M solution of (31) in ethylene 
chloride/methylene chloride (1:9) was shown to be stable for 1 day.155 Such stability of a 
hydrocarbon radical cation was unprecedented. 
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 In an attempt to synthesize an azulenyl nitrone with even lower oxidation 
potential than AZN or W-AZN, Becker et al. synthesized the novel second generation 
azulenyl nitrone, stilbazulenyl nitrone (STAZN) (32) in five efficient steps starting from 
guiazulene (18) as shown in figure 16.156 Cyclic voltammetry experiments to determine 
the oxidation potential of STAZN (32) have shown that STAZN does have an 
exceptionally low oxidation potential that is fully reversible. 
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Figure 16. Synthetic scheme of STAZN (32)  
 
For the first oxidation, the E1/2 value was found out be 0.33V vs SCE and for the second 
oxidation, E1/2 value was 0.54V vs. SCE. Owing to its low oxidation potential, STAZN 
was expected to be an improved free radical trap/antioxidant than any of the previously 
  33 
reported nitrone based spin traps.157 Lipid peroxidation assays were done to compare the 
efficacy of STAZN with other widely studied nitrone based spin traps such as PBN (2), 
S-PBN (3), NXY-059 (4), and AZN (22) and other conventional antioxidants such as 
butylated hydroxytoluene (BHT) (37), probucol (38), β-carotene (39) and vitamin E 
(40).157  
O
OH
Vitamin E (40)
HO
Butylated hydroxytoluene (37)
Beta-carotene (39)
S S
HO OH
Probucol (38)
Figure 17. Commonly used natural and synthetic antioxidants  
 
These assays were done at half the concentration of STAZN (32) as compared to other 
nitrones to compensate for the presence of an extra nitrone group in STAZN. The 
antioxidant activity of STAZN was shown to be far superior to all the other nitrones in 
this study. In fact, STAZN was shown to be more effective in inhibiting peroxidation of 
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cumene than NXY-059 (4) even at 1/100th the concentration. These assays showed that 
STAZN is in fact ca. 300 times more potent than NXY-059 in suppressing free radical 
driven peroxidation of cumene.157 It was also shown to be 2-3 orders of magnitude more 
potent that PBN (2) in this assay. Other results with this assay showed that STAZN 
markedly outperformed β-carotene, and was found to be almost as potent as BHT (37); 
however, STAZN was substantially out performed by vitamin E (40) and probucol (39) in 
a non-polar solvent medium. When the same experiment was repeated in a polar medium, 
i.e. in methanol instead of benzene, a dramatic solvent effect was seen. In methanol, 
STAZN significantly outperformed conventional antioxidants namely β-carotene, BHT, 
and probucol and rivaled the activity of vitamin E. These findings were significant 
because, for the first time, a nitrone based spin trap was demonstrating antioxidant 
potency at a level ascribed to α-tocopherol. 
 In order to assess the pharmacological potency of STAZN in traumatic brain 
injury, it was shown that STAZN markedly improves neurological and histological 
outcomes.156 Rats treated with STAZN showed improved neurological scores (6.1±0.8) 
as compared to vehicle treated rats (7.6±0.3) and total contusion area was reduced by 
63% with STAZN.156 A more elaborate animal study done on 52 rats showed that 
STAZN provides an excellent neuroprotection in a focal ischemic stroke model with 
detectable neurobehavioral improvement as early as 1 to 1.5 hours after administration of 
the first STAZN dose.158 Furthermore, in one half of STAZN treated animals, cortical 
infract was virtually abolished. Interestingly, such neuroprotection was reported only at 
total dose of 1.2-2.4 mg/kg of STAZN as compared to 700-800 mg/kg of total dose 
required of NXY-059 for equivalent neuroprotection.159-161 
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 Stilbazulenyl nitrone (STAZN) was also shown to provide neuroprotection in an 
animal model of Parkinson’s disease caused by MPTP (1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine) toxicity and in a murine model of Huntington’s disease caused by the 
neurotoxin 3-nitropropionic acid.162 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP) is known to cause depletion of dopamine in this Parkinson’s disease model and 
STAZN protected about 40% of endogenous dopamine from depletion by MPTP in this 
model. Furthermore, STAZN inhibited lipid peroxidation produced by systemic 
administration of 3-nitropropionic acid in the striatum, the cerebral cortex, and the 
cerebellum. 
 In a study done to determine the efficacy of STAZN in protecting the brain in an 
animal model of focal ischemic stroke, it was found that STAZN has respectable blood 
brain barrier permeability (2.5% of plasma level at 3 hour after i.v. infusion) along with 
56% in heart and 41% in kidney.163 The circulatory half-life of STAZN was found out to 
be ~14 hours as compared to that of ~2 hours of PBN which ensures infrequent dosing. 
Even though the metabolic fate of STAZN is currently unknown, it has been 
hypothesized to undergo hepatic metabolism as a clearance pathway.163 In addition to the 
neuroprotective activity of STAZN, the compound was also shown to be cardio-
protective in a study done to determine the effectiveness of STAZN in myocardial 
ischemia/reperfusion injury.164   
 
 This work describes the synthetic and cyclic voltammetric studies to determine 
the accessibility and oxidation potentials of novel third generation azulenyl nitrones and 
fourth generation pseudoazulenyl nitrones. 
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[2] RESEARCH OBJECTIVE 
 The objective of this research is to design and synthesize third generation azulenyl 
nitrones and various novel pseudoazulenyl nitrones with lower oxidation potentials than 
that of previously synthesized nitrones. Towards this goal, the following nitrones were 
pursued as potential targets. 
[2.1] Azulenyl nitrones:  
 It was theorized that by placing electron donating groups on the five-membered 
ring of the previously synthesized azulenyl nitrones, electron density could be increased 
which could result in azulenyl nitrones with yet lower oxidation potentials. Towards this 
goal, compound (45), a derivative of AZN (22) as well as compound (46), a derivative of 
STAZN (32), were pursued as potential targets.  
N
O
D
N
O
D
Compound (45) Compound (46)
Where, 
     D= electron donating group
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[2.2] Pseudoazulenyl nitrones: 
 Pseudoazulenes are iso-π-electronic analogues of azulenes containing heteroatom  
(S, O, or NR), which provide two mobile electrons.165 They are chemically named based 
on the type and position of heteroatom.166 For example,  
 
X
41a: X=N-R (cyclopenta[b]pyridine)
41b: X=O (cyclopenta[b]pyran)
41c: X=S (cyclopenta[b]thiopyran)
X
42a: X=N-R (cyclopenta[c]pyridine)
42b: X=O (cyclopenta[c]pyran)
42c: X=S (cyclopenta[c]thiapyran
(41) (42)  
 
Pseudoazulenes containing two heteroatoms are also known.167  
 
Y
X
Y
X
(43) (44)  
 
Studies done on theses pseudoazulenes have shown that stability and aromatic character 
decreases in the order given below. 
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YX
Y
X
Azulene (17)
>
X
X
> > >
(42) (41) (43) (44)
stability decreases
Pseudoazulenes  
 
Certain pseudoazulenes have been shown to possess antifungal properties.168  
 Pseudoazulenes, because of the presence of an electronegative heteroatom in the 
ring structure, possess lower oxidation potentials than that of corresponding benzenoid 
and counterpart. Nitrones in conjugation with pseudoazulenes, therefore, were expected 
to result in spin traps having even lower oxidation potential than those resulting from 
benzenoids and azulenes.  The general structure of these targets are as shown below: 
N
N
R
O
Compound (47)
N
O
N
N
R
O
Compound (48)
N
O
D
Where, 
      D= electron donating group and,
      R= alkyl group
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The presence of the nitrogen heteroatom in the pseudoazulenyl system permits various 
possibilities of improving or modifying the physicochemical properties of the 
pseudoazulenyl nitrone. For example, simply by changing the substituent R above, we 
were able synthesize lipophilic, hydrophilic, or amphiphilic compounds, or compounds 
that are putatively equipped to target specific organ or cell structures such as 
mitochondria. Such diversity and flexibility is warranted when designing drug candidates.  
 
[3] RESULTS AND DISCUSSION 
[3.1] Synthesis of Third Generation Azulenyl Nitrones: 
 It has been established that nitrones having low oxidation potential are efficient as 
antioxidants in trapping free radicals in vitro and likely in vivo.34,157 Therefore, it was 
decided to further lower the oxidation potentials of azulenyl nitrones by increasing the 
electron density in the five membered ring of the azulenyl system, which can be done by 
attaching electron donating groups such as hydroxyl (-OH), alkoxyl (-OR), mercapto (-
SH), or alkylthio (-SR). The vacant 1-position on bis-azulenyl monoaldehyde (49) is ideal 
for such a purpose since it is the most electronegative position in the azulene system.  
O
Bis-azulenyl monoaldehyde (49)
Vacant Postition
Azulene (17)
Most electronegative Position
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[3.1.1] Synthesis of 1-substituted bisazulenyl-mononitrone: 
 Bis-azulenyl dialdehyde (36) had already been synthesized by Becker et al.157 
Following the same protocol, bis-azulenyl dialdehyde (36) was synthesized and then 
decarbonylated by using a half equivalent of Wilkinson’s catalyst at 110°C under argon 
to give bis-azulenyl monoaldehyde (49). The bis-azulenyl monoaldehyde (49) was 
reacted with 2,2'-dithiobis-benzothiazole (Altax) (50) at 200°C in ethylene glycol to give 
bisazulenyl thiobenzothiozole monoaldehyde derivative (51) in excellent yield according 
to the procedure of Porshnev et al.169 The resulting bisazulenyl thiobenzothiozole 
monoaldehyde was then successfully converted to the mononitrone (52) by condensation 
with N-t-butyl hydroxylamine at 100oC. Various attempts to cleave the sulfur-carbon 
bond to yield 1-substituted bis-azulenyl mononitrone (53) in basic condition or with ethyl 
iodide failed.  
O
O
O
Wikinson's 
catalyst
0.5 eq
Bis-azulenyl dialdehyde (36)
Bis-azulenyl monoaldehyde (49)
S
N
S
S
N
S
Altax (50)
Ethylene glycol
200oC
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O S
S
N
N S
S
N
O
N-t-Butyl hydroxylamine
Thio benzothiazole Monoaldehyde derivative (51) Thio benzothiazole Mononitrone derivative (52)
N SH
O
N
H
OH
(53)
Figure 18. Attempted synthesis of 1-substituted thio-benzothiozole bis-azulenyl mononitrone (53)  
 
 Palei et al. showed that alkylthio groups can be introduced on the azulenyl 
derivatives at -78°C by reacting azulenes with ethylsulfenyl chloride.170 Following the 
same protocol, 1-ethylthio-bis-azulenyl-monoaldehyde (54) was synthesized with an 
ethylthio group at the 1-position. 1-substituted monoaldehyde (54) was then easily 
converted to 1-ethylthio-bis-azulenyl-mononitrone (55) by condensing the 1-ethylthio-
bis-azulenyl-monoaldehyde (54) with N-(tert-butyl)hydroxylamine. 
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O O S
N S
O
Et-S-Cl
Et-S-S-Et + SO2Cl2
N-t-Butyl hydroxylamine
Bis-azulenyl monoaldehyde (49) 1-Ethylthio bis-azulenyl monoaldehyde (54)
1-Ethylthio Bis-azulenyl mononitrone (55)
N
H
OH
Figure 19. Synthetic scheme of 1-ethylthio-bis-azulenyl mononitrone (55)  
 
Using the same protocol, a guiazulenyl nitrone with ethylthio group at 3-position (56) 
was also synthesized in three efficient steps from guiazulene. 
 First, guiazulene (18) was converted to 1-ethylthio-guiazulene (57) using the 
protocol of Palei.170 The 1-methyl group on compound (57) was oxidized by 2,3-
dichloro-5,6-dicyanobenzoquinone (DDQ) to give 3-(ethylthio)-guiazulene-1-
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carbaldehyde (58) which was then condensed with N-t-butylhydroxyl amine to give 3-
(ethylthio)-guiazulene-1-nitrone (56).  
Et-S-Cl
Et-S-S-Et + SO2Cl2
S
S S
O N
O
N-t-Butyl hydroxylamine
N
H
OH
DDQ
Guiazulene (18) 1-ethylthio-guiazulene (57)
3-(ethylthio)-guiazulene-1-carbaldehyde (58) 3-(ethylthio)-1-nitrone-guiazulene (56)
Figure 20. Synthetic scheme of 3-(ethylthio)-guiazulene-1-nitrone (56)  
  
[3.2] Synthesis of novel pseudoazulenyl dinitrones: 
 The synthesis of novel pseudoazulenyl dinitrones starts with the extraction of 
valtrate (59) from the finely ground root of Centranthus ruber (Red Valerian or Jupiter’s 
Beard) with ethanol.171 After filtration and another extraction with chloroform, crude 
valtrate was collected. For further purification, silica gel column chromatography with 
hexane/ethyl acetate (8:2) was necessary. According to the protocol by Theis, valtrate 
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was treated with an acid such as trifluroacetic acid or trichloroacetic acid, to yield yellow 
baldrinal (60).172 Recently it was discovered that baldrinal (60) could also be synthesized 
from valtrate extracted from finely ground and dried root of Valeriana officinalis using 
ethanol as solvent. Even though the yield of baldrinal obtained root of Valeriana 
officinalis is approximately 50% less than that obtained from the root of Centhranthus 
ruber, nevertheless, the dried root Valeriana officinalis is less expensive and 
conveniently available in finely ground form in bulk quantity from Pacific Botanicals. 
Baldrinal (60) was used to synthesize various pseudoazulenyl dinitrone derivatives. 
O
O
O
O
O
O
O
O
O
O
O
O
CF3COOH
Valtrate (59)
Baldrinal (60)
[After extraction from C. ruber root]
Figure 21. Synthetic scheme of Baldrinal (60)  
 
[3.2.1] Synthesis of 2-butyl-cyclopenta[c]pyridine-4,7-dinitrone (63): 
 Baldrinal (60) was converted to a 2-butyl-cyclopenta[c]pyridine4,7-dialdehyde 
(61) by treating it with n-butyl amine  according to the procedure by Seitz et al.173 Even 
though this reaction could be done without any solvent, for practical purposes, use of a 
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small amount of chloroform as a solvent was found out to be convenient for completion 
of the reaction. Compound (61) was then condensed with N-t-butyl hydroxylamine to 
yield 2-butyl-cyclopenta[c]pyridine-4,7-dinitrone (63). 
O
O
O
O
Baldrinal (60)
N
O
O
2-butyl-cyclopenta[c]pyridine-4,7-dialdehyde (61)
N
N
N
O
O
2-butyl-cyclopenta[c]pyridine-4,7-dinitrone (63)
N
H
OH
N-t-butyl hydroxylamine
NH2
n-butyl amine
Figure 22. Synthetic scheme of 2-butyl-cyclopenta[c]pyridine-4,7-dinitrone (63)  
Because STAZN possess an extremely low oxidation potential, it was decided to 
synthesize a STAZN analogue, a dimer of pseudoazulenyl dinitrone (63) containing four 
nitrone groups. Therefore, in an attempt to synthesize dimer (64), dialdehyde (61) was 
converted to the 1-bromo-dialdehyde derivative (65) via bromination with N-
bromosuccinimide (NBS). Stille coupling of compound (65) with 1,2-
bis(tributylstannyl)ethane (66) in the presence of catalytic Pd-catalyst failed to give the 
required tetra aldehyde dimer (67).  
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N
O
NBS
N
O
O
O
Br
5-bromo-2-butyl-cyclopenat[c]pyridine-
4,7-dicarbaldehyde (65)2-butyl-cyclopenta[c]pyridine-4,7-dialdehyde 
(61)
(Bu)3Sn
Sn(Bu)3
; Pd-Cat
(66)
N
O
O
N
O
O
Pseudoazulenyl Dimer (67)
Expected product
N
N
N
N
N
N
O
OO
O
Pseudoazulenyl Tetranitrone (64)
NH
HO
N-t-butyl hydroxylamine
Figure 23. Attempted synthesis of Bis-pseudoazulenyl Tetraaldehyde (67)  
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Failure to form this Stille product (67) could be the result of the fact that the 
pseudoazulenyl compounds are electron rich and may not constitute a good electrophile. 
Furthermore, bromo derivative (65) was found out to be unstable at the reaction 
temperature of 110°C, which is standard for such coupling reactions. Such instability for 
these high temperatures could be expected from compounds having such low oxidation 
potentials. 
 
[3.2.2] Synthesis of 2-(propyl imidazole)-cyclopenta[c]pyridine-4,7-dinitrone (72): 
After successfully synthesizing the first pseudoazulenyl dinitrone, 2-butyl-
cyclopenta[c]pyridine-4,7-dinitrone (63), it was decided to examine the prospect of 
incorporating greater functionality. Histamine is a biogenic amine and is involved in 
various physiological functions such as in immune responses, as a neurotransmitter and 
as a chemotactic agent.174 Reactive oxygen species are generated at inflammatory sites 
and aggravate tissue damage, which can be minimized or abrogated by scavenging these 
free radicals.  
Furthermore, the mitochondrion produces 90% of the total free radicals. These free 
radicals are formed due to the constant leakage of electrons during oxidative 
phosphorylation. As result of proton pumping, mitochondria have an overall negative 
potential. Cationic species could be targeted towards the mitochondria to scavenge free 
radicals at the site of their formation.186 Therefore, pseudoazulenyl dinitrone containing 
histamine functionality was decided as a potential synthetic target, since at physiological 
pH the nitrogen on the imidazole ring is expected to be protonated.  However, product 
(69) could not be obtained. This reaction of baldrinal (60) with histamine (70) leads to a 
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mixture of products that could not be identified by nuclear magnetic resonance (NMR) or 
mass spectrometry.  
O
O
O
O
Baldrinal (60)
N
O
O
Pseudoazulenyl dialdehyde derivative of 
histamine (69)
N
N
N
O
O
Pseudoazulenyl Dinitrone (68)
N
H
OH
N-t-butyl hydroxylamine
N
N
H
NH2
N
NH
N
NH
(70)
Figure 24. Attempted synthesis of Pseudoazulenyl Dialdehyde (69)  
 
Since histamine did not yield the required product, another derivative containing 
imidazole ring was successfully synthesized. Similar to histamine, this dinitrone, 2-
(propyl imidazole)-cyclopenta[c]pyridine-4,7-dinitrone (72), is expected to be partially 
protonated at physiological pH. 
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O
O
O
O
Baldrinal (60)
N
O
O
2-(propyl imidazole)-cyclopenta[c]pyridine-4,7-
dicarbaldehyde (71)
N
N
N
O O
2-(propyl imidazole)-cyclopenta[c]pyridine-4,7-dinitrone
(72)
N
H
OH
N-t-butyl hydroxylamine
N
N
N
NH2
N
N
N
At Physiological PH (7.4)
N
N
N
O O
Protonated form of (72)
N
N
H
1-(3-aminopropyl)-imidazole
Figure 25.  Synthetic scheme of 2-(propyl imidazole)-cyclopenta[c]pyridine-4,7-dinitrone (72)  
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[3.2.3] Synthesis of 2-(3-(dimethylamino)propyl)-cyclopenta[c]pyridine-4,7-dinitrone 
(75): 
Another nitrogen containing pseudoazulenyl dinitrone derivative, 2-(3-
(dimethylamino)propyl)-cyclopenta[c]pyridine-4,7-dinitrone (75) was synthesized by 
treating N,N-dimethylpropane-1-3-diamine with baldrinal (60) to get dialdehyde (74), 
which was then condensed with N-tert-butyl hydroxylamine to give dinitrone (75). 
O
O
O
O
Baldrinal (60)
N
O
O
N
N
N
O
O
N
H
OH
N-t-butyl hydroxylamine
N
N
NH2
N
N,N-dimethylpropane-1,3-diamine
2-(3-(dimethylamino)propyl)-
cyclopenta[c]pyridine-4,7-dicarbaldehyde (74)
2-(3-(dimethylamino)propyl)-cyclopenta[c]pyridine-4,7-dinitrone (75)
Figure 26. Synthetic scheme of 2-(3-(dimethylamino)propyl)-cyclopenta[c]pyridine-4,7-dinitrone (75)  
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[3.2.4] Synthesis of spermine analogue (86): 
Spermine (76) and spermidine (77) are biogenic polyamines required by both 
prokaryotes and eukaryotes for cell growth and differentiation.175 At physiologic pH, 
these polyamines exist as poly-cations.  
 
H2N N
H
H
N NH2
spermine (76)
H2N N
H
NH2
spermidine (77)  
 
Interestingly, despite the fact that mitochondria lack biosynthetic pathways for these 
polyamines, substantial amounts of spermine and spermidine were detected in the 
mitochondrial matrix.176 These polyamines are known to bind to DNA.177 Furthermore, 
spermine was shown to exert antioxidative free radical scavenging activity even at 
submillimolar concentration, thereby protecting DNA against oxidative stress.178,179 Since 
DNA is constantly under oxidative attack, it was proposed that incorporating spermine-
like structures into pseudoazulenyl nitrones might bolster the antioxidative effect of 
spermine and better attenuate oxidative damage to DNA strands. Furthermore, since 
spermine is cationic at physiological pH, it might help direct pseudoazulenyl nitrone-
polyamine conjugates to mitochondria.  
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 One such naturally occurring polyamine-antioxidant conjugate that is active in 
mitochondria is trypanothione (79), a unique spermidine/glutathione derivative from 
trypanosomes and leishmania. Trypanosomes and leishmania are parasitic protozoa 
responsible for African sleeping sickness, Chagas’ disease and leishmaniasis. These 
parasites were found to be surprisingly tolerant to oxidative stress. Even though they 
contain glutathione, the lack of glutathione reductase in these parasites generated interest 
in knowing their mechanism for oxidative detoxification. Fairlamb et al. (1985) reported 
isolation of the unique glutathione derivative from trypanosomes (also present in 
leishmania), which they called trypanothione [N1,N8-bis(glutathionyl) spermidine] 
(79).180 Trypanothione, which is the two electron reduced form of trypanothione disulfide 
(T[S]2) (78), has a unique structure containing two glutathione moieties coupled to a 
spermidine unit by peptide bonds. The reduction of T[S]2 to trypanothione is carried out 
by trypanothione reductase which is similar to glutathione reductase.181 At physiologic 
pH, the -SH groups of trypanothione are more reactive than those of glutathione.182 
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Figure 27. Trypanothione  
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Towards the goal of synthesizing a conjugated spermine pseudoazulenyl dinitrone, 
spermine (76) was treated with baldrinal (60), but unfortunately, the spermine-
pseudoazulenyl  dialdehyde derivative (80) could not be obtained. 
 
O
O
O
O
Baldrinal (69)
N
O
O
Spermine-Pseudoazulenyl dialdehyde (80)
H2N N
H
H
N NH2
spermine (76)
NH
HN
NH2
Figure 28. Attempted synthesis of Spermine derivative of pseudoazulenyl dialdehyde (80)  
  
From the failed reactions of baldrinal with spermine and histamine, it was thought 
that the secondary amine group might be reacting with the aldehyde group to form 
iminium salts. Therefore, it was decided to attempt to synthesize a 1,4-Bis(3-
aminopropyl)-piperazine derivative (81)  that lacks the secondary amino groups. But even 
this product (81) was elusive. 
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N
NH2N
NH2
O O
O
O
Baldrinal (60)
N
O
O
Piperazine analogue (81)
N
N
H2N
1,4-bis(3-aminopropyl)-piperazine (82)
Figure 29. Attempted synthesis of piperazine  derivative of pseudoazulenyl dinitrone (81)  
 
After failing to get the required spermine analogue, it was decided to pursue the synthesis 
of a spermine analog from the 2-(3-(dimethylamino)propyl)-cyclopenta[c]pyridine-4,7-
dinitrone (75). Therefore, compound (75) was treated with 1,4-diiodobutane (83) to get 
compound (84) which was successively treated with N1,N1,N3,N3-tetramethylpropane-1,3-
diamine (85) to get dicationic species (86). This highly polar compound was difficult to 
purify. Nevertheless, support for the assigned structure was obtained by mass 
spectroscopy with detection of a strong peak at m/z=293.2. 
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N
N
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Dimethylamino propyl dinitrone (75)
(84)
N,N,N',N'-tetramethylpropane-1,3-diamine (85)
Spermine analogue (86)
1,4-diiodobutane (83)
Figure 30. Synthetic scheme of dicationic spermine analogue of pseudoazulenyl dinitrone (86)  
 
[3.2.5] Synthesis of 2-octadecyl-cyclopenta[c]pyridine-4,7-dinitrone (88): 
 Targeted drug delivery to the brain has received considerable attention in recent 
times.185 Because the brain cell membranes are rich in polyunsaturated fatty acids 
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(PUFAs), as a rule, lipophilic molecules more easily pass through the BBB. Therefore, 
increasing the lipophilicity of organic molecules is an often applied strategy to direct 
drug molecules into the brain.184 Towards this goal, to impart lipophilicity to 
pseudoazulenyl nitrones, 2-octadecylamine-cyclopenta[c]pyridine-4,7-dinitrone (88), a 
pseudoazulenyl dinitrone containing a long hydrophobic alkyl chain was synthesized. 
O
O
O
O
Baldrinal (60)
N
H
OH
N-t-butyl hydroxylamine
NH2-(CH2)17-CH3
Octadecylamine
N
H
O O
H
H2C 17
CH3
N
H
N N
H
H2C 17
CH3
O
O
2-octadecyl-cyclopenta[c]pyridine-4,7-
dicarbaldehyde (87)
2-octadecyl-cyclopenta[c]pyridine-4,7-dinitrone (88)
Figure 31. Synthetic scheme of 2-octadecyl-cyclopenta[c]pyridine-4,7-dinitrone (88)  
 
[3.2.6] Synthesis of 2-(6-hexanol)-cyclopenta[c]pyridine-4,7-dinitrone (91): 
6-hydroxyhexyl containing pseudoazulenyl dinitrone derivative was synthesized 
by treating 6-aminohexan-1-ol (89) with baldrinal (60) to get dialdehyde (90), which was 
then condensed with N-tert-butyl hydroxylamine to give 2-(6-hexanol)-
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cyclopenta[c]pyridine-4,7-dinitrone (91). The advantage of having hydroxyl functionality 
is that it can be easily modified or functionalized.  
O
O
O
O
Baldrinal (60)
N
O
O
2-(6-hexanol)-cyclopenta[c]pyridine-4,7-
dicarbaldehyde (90)
N
N
N
O
O
N
H
OH
N-t-butyl hydroxylamine
6-aminohexanol (89)
OH
H2N
OH
HO
2-(6-hexanol)-cyclopenta[c]pyridine-4,7-dinitrone (91)
Figure 32. Synthetic scheme of 2-(6-hexanol)-cyclopenta[c]pyridine-4,7-dinitrone (91)  
 
[3.2.7] Synthesis of 2-butyl-5-ethylthio-cyclopenta[c]pyridine-4,7-dinitrone (94): 
After cyclic voltammetric studies revealed that the oxidation potential of the 
pseudoazulenyl bis-nitrones were slightly higher than that of STAZN, it was decided to 
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pursue the preparation of pseudoazulenyl dinitrones that were equipped with electron-
donating alkylthio groups. 
Experiments to introduce an electron donating group at the 1-position of 
pseudoazulenyl dinitrones were performed. Using the protocol of Palei,170 1-ethylthio 
substituted pseudoazulenyl dialdehyde (92) was synthesized by reacting dialdehyde (61) 
with ethyl sulfenyl chloride (93). 1-ethylthio substituted dialdehyde (92) was converted to 
1-ethylthio substituted dinitrone (94) by condensation with N-tert-butyl hydroxyl amine. 
N
O
O
2-butyl-cyclopenta[c]pyridine-4,7-dicarbaldehyde (61)
Et-S-Cl  (93)
Et-S-S-Et + SO2Cl2
N
O
O
S
N
N
SO
N
O
2-butyl-5-(ethylthio)-
cyclopenta[c]pyridine-4,7-dicarbaldehyde (92)
N
H
OH
N-t-butyl hydroxylamine
2-butyl-5-(ethylthio)-
cyclopenta[c]pyridine-4,7-nitrone (94)
Figure 33. Synthetic scheme of 2-butyl-5-(ethylthio)-cyclopenta[c]pyridine-4,7-dinitrone (94)  
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[3.3] Cyclic Voltammetry:  
Cyclic voltammetry experiments were performed to determine the oxidation 
potential of 2-butyl-5-ethylthio-cyclopenta[c]pyridine-4,7-dinitrone (94). The results 
were compared to STAZN (32) under the same conditions, since STAZN was in 
possession of the lowest recorded oxidation potential for the nitrone-based spin traps. 
The cyclic voltammogram of 2-butyl-5-ethylthio-cyclopenta[c]pyridine-4,7-
dinitrone (94) clearly shows that the oxidation potential of this compound is lower than 
that of STAZN.  As can be seen from figure 34, the oxidation of compound (94) is fully 
reversible with first oxidation occurring at 0.31 V vs SCE. As compared to STAZN (first 
oxidation at 0.45 V vs SCE) (figure 35), the first oxidation potential for pseudoazulenyl 
nitrone (94) is more than 100 mV lower.  
 
Figure 34. Cyclic voltammogram of 2-butyl-5-ethylthio-cyclopenta[c]pyridine-4,7-dinitrone (94)
A solution of compound (94) in CH2Cl2 at a 100 mM with scan rate of 100 mV s
-1 and glassy carbon working 
electrode. The electrolyte is tetrabutylammonium hexaflurophosphate (TBAPF6) at a concentration of 100 mM.  
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Figure 35.   Cyclic voltammogram of STAZN (32)
A solution of STAZN (32) in CH2Cl2 at a 100 mM with scan rate of 100 mV s
-1 and glassy carbon working 
electrode. The electrolyte is tetrabutylammonium hexaflurophosphate (TBAPF6) at a concentration of 100 mM.  
 
[4] CONCLUSION 
It has been more than 60 years since Commoner et al. first brought attention to the 
harmful effects of free radicals on biological systems.1 Since then, reactions of free 
radicals have been widely studied in vivo and in vitro to fully understand their chemical 
and biological fate. Over the years, nitrones have shown enormous potential as free 
radical traps. The ability of nitrones to trap free radicals and form stable nitroxide has led 
to hypotheses that nitrones could act as chain-breaking antioxidants and prevent damages 
caused by free radicals in biological systems. Surely, nitrones are emerging as potential 
drug candidates in diseases like stroke, ischemic heart disease (IHD) and aging, as well as 
neurodegenerative diseases like Alzheimer’s, Parkinson’s and Huntington’s disease. 
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However, many of the nitrones studied by others possess unusually high oxidation 
potential.  
Earlier, Becker et al. have successfully synthesized azulenyl nitrones with 
oxidation potentials much lower than any of the previously synthesized nitrones and close 
to those of endogenous biological antioxidants.157 In this study, synthesis of a nitrone 
with an oxidation potential significantly lower than that of the much heralded STAZN 
was accomplished. 
Towards this goal to synthesize nitrone with oxidation potential lower than that of 
STAZN, range of structurally diverse nitrones and a particular novel pseudoazulenyl 
dinitrone was synthesized. The presence of the nitrogen heteroatom in the pseudoazulenyl 
structure was strategically exploited to synthesize various dinitrone congeners, which 
theoretically could render pseudoazulenyl dinitrones mitochondriotropic. These 
pseudoazulenyl dinitrones are anticipated to have increased bioavailability than any of 
the previously synthesized nitrones. However, the oxidation potentials of these 
pseudoazulenyl dinitrones were found out to be slightly higher than that of STAZN.  
In order to synthesize nitrones with oxidation potentials even lower than that of 
STAZN, pseudoazulenyl dinitrone (94) with an electron donating group at 1-position was 
synthesized. Cyclic voltammetry studies have shown that 1-ethylthio substituted 
pseudoazulenyl dinitrone (94) does indeed possess an oxidation potential more than 100 
mV lower than STAZN. Based on these results, 1-substituted pseudoazulenyl dinitrone 
(94) is expected to be an even more efficient free radical trap than STAZN. 
The importance of this research resides in the expedient synthetic protocol 
described to prepare a diverse array of highly electron-rich pseudoazulenyl dinitrones. 
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Starting with the dried ground root of Centranthus ruber or Valeriana officinalis, various 
pseudoazulenyl dinitrones were synthesized in four efficient steps. Moreover, further 
one-step modification of this pathway has resulted in the preparation of a pseudoazulenyl 
dinitrone in possession of the lowest oxidation potential recorded for any of the nitrone 
based spin trap yet examined. Further studies to evaluate the efficacy of these novel 
pseudoazulenyl dinitrones in animal models of stroke and neurodegenerative diseases, 
like Alzheimer’s, Parkinson’s and Huntington’s disease are underway. 
 
[5] EXPERIMENTAL SECTION  
General procedure 
All proton (1H) NMR and carbon (13C) NMR measurements were recorded on Bruker 
AVANCE-400 spectrometer. All low resolution mass spectra were recorded on Finnigan 
Navigator LC/MS instrument by using direct injection into the mass spectrometer and 
detecting molecular ion mass with Atmospheric Pressure Chemical Ionization (APCI). 
Thin layer chromatography (TLC) was performed by using silica gel 60 F254. Column 
chromatography was performed using 60Å (230-400 mesh). 
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[5.0.1] Synthesis of bis-guiazulenyl monoaldehyde (49): 
Bis-guiazulenyl dialdehyde (49)  (342 mg, 0.74 mmol)  
and Wilkinson’s catalyst, chlorotris(triphenylphosphine) 
rhodium(I), (680 mg , 73 mmol) were mixed in 8 ml of 
toluene. The reaction mixture was heated at 110 °C for 12 
h under argon. Silica gel thin layer chromatography 
showed non-polar green di-decarboxylated compound 
followed by greenish brown product. Product was 
purified via silica gel column chromatography using hexane as the solvent until all green 
di-decarboxylated product was collected and then the solvent polarity was increased by 
the use of a 20:1 hexane/ethyl acetate solvent system until 104 mg (34%) of 
monoaldehyde (49) was collected. Rf = 0.23 (Hexane/ethyl acetate 9:1) 
1H NMR (400 MHz, CDCl3): δ 10.36 (s, 1H), 9.60 (d, J=1.8 Hz, 1H), 8.39 (s, 1H), 8.12 
(d, J=1.8 Hz, 1H), 8.06 (d, J=4.2 Hz, 1H), 7.85 (d, J=15.4 Hz, 1H), 7.64 (d, J=15.4 Hz, 
1H), 7.54 (dd, J=10.7, 1.9 Hz, 1H), 7.32-7.26 (m, 2H), 7.25 (m, 1H), 6.96 (d, J=10.5 Hz, 
1H), 3.19-3.10 (m, 7H), 3.10-2.93 (m, 1H), 1.39 (d, J=6.9 Hz, 6H), 1.34 (d, J=6.9 Hz, 
6H). 13C NMR: (400 MHz, CDCl3): δ 186.66, 149.84, 149.14, 147.08, 143.80, 142.34, 
141.83, 141.73, 139.72, 137.60, 137.33, 135.50, 134.98, 132.68, 132.60, 130.93, 129.25, 
129.05, 128.08, 127.32, 125.03, 124.33, 119.61, 38.18, 37.64, 28.71, 24.53, 24.41. 
LRMS: (LC/MS-APCI, MeOH) m/e 435.2 (MH+). 
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[5.0.2] Synthesis of bis-azulenyl thio-benzothiazole monoaldehyde derivative (51): 
Bis-guiazulene monoaldehyde (49) (242 mg, 0.57 mmol) 
was mixed with 2,2'-dithiobisbenzothiazole (altax) (50) 
(211 mg, 0.63 mmol) and 5 ml of ethylene glycol was 
added. The reaction mixture was heated at 220 °C for 2.5 
h under argon. Silica gel thin layer chromatography 
showed greenish-brown product running slower than 
starting material. When the starting material had 
disappear, as determined by silica gel thin layer chromatography, the reaction was 
stopped and partitioned between water and chloroform to remove the ethylene glycol. 
The chloroform layer was collected and the volume was reduced by rotary evaporator to 
provide a dense black oil. The product was purified via silica gel column chromatography 
with 8:2 hexane:ethyl acetate. After purification, 211 mg (58%) of product was collected. 
Rf = 0.38 (hexane/ethyl acetate 7:3). 
1H NMR: (400 MHz, CDCl3): δ 10.39 (s, 1H), 9.61 (d, J=1.6 Hz, 1H), 8.68 (d, J=1.8 Hz, 
1H), 8.41 (s, 1H), 8.34 (s, 1H), 7.87 (d, J=8.1 Hz, 1H), 7.77 (d, J=15.6 Hz, 1H), 7.65 (d, 
J=15.5 Hz, 1H), 7.58-7.52 (m, 2H), 7.49 (dd, J=11.0, 2.0 Hz, 1H), 7.39-7.36 (m, 2H), 
7.27 (d, J=1.9 Hz, 1H), 7.24 (d, J=2.0 Hz, 1H), 3.19 (s, 3H), 3.17-3.12 (m, 4H), 3.08-
3.03 (m, 1H), 1.39 (d, J=6.9 Hz, 6H), 1.29 (d, J=6.9 Hz, 6H). 13C NMR: (400 MHz, 
CDCl3): δ 186.84, 154.75, 150.08, 149.72, 149.06, 145.48, 143.21, 142.57, 142.12, 
141.84, 140.15, 137.99, 137.93, 137.61, 136.63, 136.27, 135.89, 133.16, 131.08, 130.37, 
129.23, 126.50, 126.30, 126.05, 125.65, 124.20, 123.04, 121.97, 121.09, 112.13, 38.40, 
38.04, 29.10, 29.05, 24.67, 24.60. LRMS: (LC/MS-APCI, MeOH) m/e 586.3 (MH+). 
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[5.0.3] Synthesis of thio-benzothiazole-mononitrone derivative (52): 
 Bis-azulenyl thio-benzothiazole monoaldehyde 
derivative (51) (141 mg , 0.24 mmol), t-butyl 
hydroxyl amine (60 mg, 0.48 mmol,) and 
magnesium sulfate (58 mg, 0.48 mmol) were mixed 
with 1 ml of pyridine. Reaction mixture was heated 
at 90 °C for 14 h. After 14 h, silica gel thin layer 
chromatography indicated that all the starting 
material had reacted. The reaction was stopped and 
product was purified via silica gel column chromatography using hexane/ethyl acetate 
(7:3) as eluent. 96 mg (61%) of product was collected. Rf = 0.27 (hexane/ethyl acetate 
1:1). 
1H NMR: (400 MHz, CDCl3): δ 9.73 (s, 1H), 8.66 (d, J=2.0 Hz, 1H), 8.30 (s, 1H), 8.18 
(s, 1H), 8.12 (d, J=1.7 Hz, 1H), 7.91-7.86 (m, 2H), 7.73 (d, J=15.5 Hz, 1H), 7.54 (dd, 
J=7.9, 0.46 Hz, 1H), 7.47 (dd, J=10.7, 1.9 Hz, 1H), 7.39-7.34 (m, 2H), 7.21-7.17 (m, 
2H), 7.06 (d, J=10.6 Hz, 1H), 3.21 (s, 3H), 3.12 (s, 3H), 3.05 (m, 2H), 1.73 (s, 9H), 1.36 
(d, J=6.8 Hz, 6H), 1.28 (d, J=6.9 Hz, 6H). 13C NMR: (400 MHz, CDCl3): δ 154.81, 
149.56, 148.07, 145.05, 143.49, 143.09, 142.74, 141.61, 137.61, 137.48, 136.34, 136.24, 
136.22, 135.98, 135.88, 132.05, 130.87, 130.60, 130.39, 129.99, 126.58, 126.20, 126.16, 
124.08, 123.31, 121.89, 121.15, 118.96, 111.82, 69.88, 38.37, 38.02, 30.04, 29.24, 28.91, 
24.68, 24.62. LRMS: (LC/MS-APCI, MeOH) m/e 657.2 (MH+). 
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[5.0.4] Synthesis of sulfenyl chloride (93): 
S
Cl
  
A solution of 1,2-diethyldisulfide (100 mg, 0.82 mmol) was prepared by dissolving it in 3 
ml of dry methylene chloride. This solution was kept under argon and cooled to 0 °C on 
an ice bath. Another solution of sulfuryl chloride (110.4 mg, 0.82 mmol) in 5 ml of dry 
methylene chloride was prepared and was added slowly to diethyldisulfide solution over 
a period of 10 min with vigorous stirring under argon. After stirring for 10 min, this 
solution was kept at -70 °C in a dry-ice/acetone bath. This freshly prepared solution 
containing sulfenyl chloride (Et-S-Cl) was used for further synthesis. 
 
[5.0.5] Synthesis of 1-ethylthio bis-guiazulenyl monoaldehyde (54):  
Bis-guiazulenyl monoaldehyde (49) (71 mg, 0.16 mmol) 
was dissolved in 15 ml of dry hexane and 1 ml of dry 
methylene chloride and cooled to -70 °C in a dry-
ice/acetone bath while under argon. Ethyl sulfenyl 
chloride (93) (1.7 ml, 0.17 mmol) solution was added 
slowly over a period of 30 min with vigorous stirring and 
evacuation. After all the ethyl sulfenyl chloride solution 
was added, the reaction mixture was stirred for additional 30 min and then slowly 
brought back to room temperature over a period of 60-90 min. A layer of chloform was 
added and the reaction mixture was extracted with saturated sodium bicarbonate to 
neutralize acid. The chlorform layer was evaporated to a thick black oil that was purified 
O S
(54)
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via silica gel column chromatography with 9:1 hexane/ethyl acetate as eluent. After 
purification, 31 mg (38%) of pure product (54) was collected. Rf = 0.21 (hexane/ethyl 
acetate 9:1). 
1H NMR: (400 MHz, CDCl3): δ 10.36 (s, 1H), 9.61 (d, J=1.8 Hz, 1H), 8.65 (d, J=2.0 
Hz, 1H), 8.38 (s, 1H), 8.15 (s, 1H), 7.78 (d, J=15.5 Hz, 1H), 7.63 (d, J=15.5 Hz, 1H), 
7.56 (dd, J=10.6, 1.9 Hz, 1H), 7.37-7.31 (m, 2H), 7.00 (d, J=10.6 Hz, 1H), 3.17 (s, 3H), 
3.11 (s, 3H), 3.22-3.04 (m, 2H), 2.82 (q, J=7.3 Hz, 2H), 1.39 (d, J=6.9 Hz, 6H), 1.37 (d, 
J=7.0 Hz, 6H), 1.24 (t, J=7.0 Hz, 3H). 13C NMR: (400 MHz, CDCl3): δ 186.85, 150.07, 
149.52, 147.57, 143.32, 143.29, 142.05, 141.92, 140.78, 140.01, 137.92, 137.87, 136.68, 
136.57,134.66, 132.94, 130.90, 129.21, 128.11, 127.01, 125.17, 125.08, 119.99, 38.39, 
38.05, 32.18, 30.05, 28.99, 28.96, 24.68, 15.68. LRMS: (LC/MS-APCI, MeOH) m/e 
481.0 (MH+). 
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[5.0.6] Synthesis of 1-ethylthio bis-guiazulenyl mononitrone (55):  
1-Ethylthio bis-guiazulenyl monoaldehyde (54) (21 
mg, 0.04 mmol) was mixed with N-t-
butylhydroxylamine (11 mg, 0.08 mmol) and 
magnesium sulfate (10.5 mg, 0.08 mmol) in 3 ml of 
anhydrous pyridine. The reaction mixture was stirred 
at 50 °C under argon for 48 h. The crude product 
was partitioned between water and chloroform. The 
chloroform layer was evaporated and the residue was purified via silica gel column 
chromatography using 8:2 hexane/ethyl acetate as eluent. After purification, 18 mg (74%) 
of product was collected. Rf = 0.10 (Hexane/ethyl acetate 7:3). 
1H NMR (400 MHz, CDCl3): δ 9.70 (s, 1H), 8.61 (d, J=2.1 Hz, 1H), 8.17 (s, 1H), 8.11 
(s, 1H), 8.10 (d, J=1.8 Hz, 1H), 7.88 (d, J=15.5 Hz, 1H), 7.70 (d, J=15.5 Hz, 1H), 7.35 - 
7.30 (m, 2H), 7.04 (d, J=10.4 Hz, 1H), 6.86 (d, J=10.7 Hz, 1H), 3.09 (s, 3H), 3.09 (s, 
3H), 3.07-3.02 (m, 2H), 2.80 (q, J=7.3 Hz, 2H), 1.73 (s, 9H), 1.36 (d, J=6.9 Hz, 12H), 
1.23 (t, J=7.3 Hz, 3H). 13C NMR (400 MHz, CDCl3): δ 148.07, 143.25, 143.12, 142.85, 
141.62, 141.01, 137.59, 136.54, 136.29, 136.12, 135.70, 135.61, 134.60, 131.92, 131.06, 
130.14, 128.88, 128.88, 126.72, 125.77, 123.24, 119.64, 119.01, 69.89, 38.36, 38.04, 
32.14, 29.17, 29.09, 28.94, 24.66, 14.55, 15.68. LRMS: (LC/MS-APCI, MeOH) m/e 
552.1 (MH+). 
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[5.0.7] Synthesis of 3-(ethylthio)-guiazulene (57): 
Guiazulene (57) (162 mg, 0.81 mmol) was dissolved in 
40 ml of dry hexane and the resulting solution was 
cooled to -70 °C in a dry-ice/acetone bath while under 
argon. Ethyl sulfenyl chloride (93) (8ml, 0.81 mmol) 
solution was added slowly over a period of 30 min with 
vigorous stirring and evacuation. After all the ethyl sulfenyl chloride solution was added, 
the reaction mixture was stirred for additional 30 min and then slowly brought back to 
room temperature over a period of 60-90 min. A layer of chloform was added and the 
reaction mixture was partitioned between chloroform and aqueous saturated sodium 
bicarbonate. The chloroform layer was evaporated to get a dark green oil, which was 
purified via silica gel column chromatography with hexane/ethyl acetate (20:1) as eluent. 
After purification, 140 mg (66%) of pure product (57) was collected. Rf = 0.26 (Hexane). 
1H NMR (400 MHz, CDCl3): δ 8.03 (d, J=2.1 Hz, 1H), 7.61 (s, 1H), 7.28 (dd, J=10.7, 
2.0 Hz, 1H), 6.86 (d, J=10.7 Hz, 1H), 3.24 (s, 3H), 3.06-2.96 (m, 1H), 2.91 (q, J=7.3, 
2H), 2.61 (s, 3H), 1.34 (d, J=6.9 Hz, 6H), 1.29 (t, J=7.3 Hz, 3H). 13C NMR (400 MHz, 
CDCl3): δ 147.46, 141.54, 140.07, 138.96, 135.66, 135.25, 133.71, 127.76, 125.04, 
117.65, 37.92, 32.08, 27.35, 24.77, 14.74, 13.13. LRMS: (LC/MS-APCI, MeOH) m/e 
259.0 (MH+). 
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[5.0.8] Synthesis of 3-(ethylthio)-1-carbaldehyde guiazulene (58): 
3-(Ethylthio)-guiazulene (57) (316 mg, 1.22 mmol) was 
dissolved in 100 ml of acetone/water (9:1) mixture. 2,3-
dichloro-5,6-dicyanobenzoquinone (DDQ) (555 mg, 2.44 
mmol) was added and reaction mixture was stirred at room 
temperature. After 10 min, silica gel thin layer 
chromatography showed no starting material. 20 ml of 
saturated sodium bicarbonate and 20 ml saturated sodium bisulfite solution was added to 
neutralize and reduce unreacted DDQ. The crude product was isolated by extraction with 
chloroform. A layer of water was added to facilitate the extraction. The chloroform layer 
was collected and evaporated using a rotary evaporator. After purifying the product via 
silica gel column chromatography using hexane/ethyl acetate (9:1) as eluent, 164 mg 
(49%) of product (58) was collected. Rf = 0.47 (Hexane/Ethyl acetate 9:1) 
1H NMR (400 MHz, CDCl3): δ 10.27 (s, 1H), 9.61 (d, J=2.0 Hz, 1H), 8.10 (s, 1H), 7.58 
(dd, J=10.8, 2.1 Hz, 1H), 7.33 (d, J=10.8 Hz, 1H), 3.32 (s, 3H), 3.2-3.0 (m, 1H), 2.95 (q, 
J=7.3 Hz, 2H), 1.38 (d, J=6.9 Hz, 6H), 1.32 (t, J=7.3 Hz, 3H). 
13C NMR: (400 MHz, CDCl3): δ 186.17, 151.41, 149.54, 145.29, 142.04, 141.65, 
138.54, 137.776, 133.60, 124.91, 122.11, 38.34, 31.50, 27.96, 24.68, 14.48. LRMS: 
(LC/MS-APCI, MeOH) m/e 273.0 (MH+). 
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[5.0.9] Synthesis of 3-(ethylthio)-1-nitrone-guiazulene (56): 
3-(Ethylthio)-1-carbaldehyde guiazulene (58) (24 mg, 
0.08 mmol) was dissolved in 3 ml pyridine. N-t-butyl 
hydroxyl amine HCl (21 mg, 0.16 mmol) and 
magnesium sulfate (20 mg, 0.16 mmol) were added. The 
reaction mixture was stirred under argon at 95 °C for 14 
h at the end of which silica gel thin layer 
chromatography showed no starting material. After 
purification via silica gel column chromatography using hexane/ethyl acetate (7:3) as 
eluting solvent, 17 mg (58%) of greenish product (56) was collected. Rf = 0.21 
(hexane/ethyl acetate 7:3). 
1H NMR (400 MHz, CDCl3): δ 9.39 (s, 1H), 8.10 (s, 1H), 8.06 (d, J=1.9 Hz, 1H),  7.32 
(dd, J=10.7, 1.8 Hz, 1H), 6.97 (d, J=10.7 Hz, 1H), 3.22 (s, 3H), 3.10 (q, J=7.3 Hz, 2H), 
3.0-2.9 (m, 1H), 1.70 (s, 9H), 1.36-1.32 (m, 9H). 13C NMR (400 MHz, CDCl3): δ 149.23, 
142.56, 140.22, 138.96, 136.91, 136.89, 132.02, 130.25, 123.84, 122.82, 118.76, 69.80, 
38.27, 30.52, 28.88, 27.49, 24.64, 14.51. LRMS: (LC/MS-APCI, MeOH) m/e 344.0 
(MH+). 
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[5.1.0] Extraction of valtrate (59):  
100 g of finely grounded root of Centranthus ruber (Red 
Valerian) was stirred in 800 mL of ethanol for 15 min. 
After performing vacuum filtration and evaporating the 
ethanol using a rotary evaporator, the crude valtrate was 
obtained in the form of thick paste.  A layer of chloroform 
was added, which was filtered and the filtrate was 
collected. This filtrate contains fairly pure valtrate (59). 
After performing silica gel column chromatography with 
hexane/ethyl acetate (8:2) as eluent, 9.2 g (9.2%) of valtrate (59) was obtained. Rf = 0.23 
(hexane/ethyl acetate 8:2). 
1H NMR (400 MHz, CDCl3): δ 6.68 (s, 1H), 5.96 (d, J=10.1 Hz, 1H), 5.84 (t, J=2.7 Hz, 
1H), 5.35 (d, J=2.7 Hz, 1H), 4.68 (dd, J=28.9, 12.3 Hz, 2H), 3.41 (dd, J=10.1, 2.4 Hz, 
1H), 3.94 (dd, J=47.7, 4.8 Hz, 2H), 2.22-2.21 (m, 2H), 2.20 (m, 2H), 2.18-2.06 (m, 2H), 
2.03 (s, 3H), 0.96 (d, J=6.6 Hz, 6H), 0.92 (d, J=6.5 Hz, 6H). 13C NMR (400 MHz, 
CDCl3): δ 172.43, 170.85, 170.28, 148.48, 140.91, 116.63, 108.34, 92.57, 83.04, 64.15, 
60.81, 47.85, 43.36, 43.02, 43.00, 25.79, 25.57, 22.31, 22.30, 22.19, 20.90. LRMS: 
(LC/MS-APCI, MeOH) m/e 423.2 (MH+). 
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[5.1.1] Synthesis of baldrinal (60): 
Valtrate (59) (9.2 g, 21.7 mmol) was dissolved in 20 ml of 
chloroform at room temperature. In another flask, 
trifluoroacetic acid (20 g, 17.5 mmol) was dissolved in 40 
ml of chloroform. This trifluroacetic acid solution was 
added to the solution containing valtrate. The clear valtrate solution became dark 
green/blue after stirring for 5 min. When silica gel thin layer chromatography showed no 
valtrate, l60 ml of chloroform was added and washed with water until pH-4 was reached. 
A mixture of saturated aqueous NaCl solution and   saturated aqueous  NaHCO3 solution 
(1:1) was added until the pH-7 was reached. At this point, the solution turned yellow-
brown. This solution was carefully extracted successively with chloroform, where the 
yellow chloroform layer was collected. After evaporating the chloroform using a rotary 
evaporator, the product was further purified by performing silica gel column 
chromatography with hexane/ethyl acetate (8:2) as eluting solvent. 1.1 g of baldrinal (60) 
(23%) was collected as a yellow solid. Rf = 0.21 (Hexane/Ethyl acetate 8:2).  
Baldrinal (60) can also be obtained from valtrate extracted from finely ground and dried 
root of Valeriana officinalis using the same protocol. Starting with 100 gm of finely 
ground and dried root of Valeriana officinalis, 500 mg of baldrinal (60) was obtained 
which is approximately 55% less yield of baldrinal as compared to the baldrinal obtained 
from the root of Centhranthus ruber.   
1H NMR (400 MHz, CDCl3): δ 9.93 (s, 1H), 9.09 (s, 1H), 7.89 (s, 1H), 7.87 (d, J=3.28 
Hz, 1H), 6.61 (dd, J=3.26, 0.58 Hz, 1H), 5.26 (d, J=0.42 Hz, 2H), 2.12 (s, 3H). 13C 
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NMR: (400 MHz, CDCl3): δ 185.04, 170.73, 150.78, 146.33, 142.24, 133.91, 124.99, 
123.13, 119.45, 109.61, 60.57, 20.88. LRMS: (LC/MS-APCI, MeOH) m/e 219.0 (MH+). 
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[5.1.2] Synthesis of 2-butyl-cyclopenta[c]pyridine-4,7-dicarbaldehyde (61): 
Baldrinal (60) (2.5 g, 11 mmol) was dissolved in 4 ml of 
chloroform. n-butyl amine (4.38 g, 60 mmol) was added. After 
stirring for 10 min at room temperature, color changed from 
yellow to orange/red. When silica gel thin layer chromatography 
showed no baldrinal, the excess of amine was removed under 
vacuum. After performing silica gel column chromatography with 
hexane/ethyl acetate (8:2) as eluent, 272 mg (11%) of wine colored product (61) was 
collected. Rf = 0.90 (chloroform/methanol 99:1). 
1H NMR (400 MHz, CDCl3): δ 10.25 (s, 1H), 9.92 (s, 1H), 9.03 (s, 1H), 7.97 (d, J=3.6 
Hz, 1H), 7.84 (d, J=1.5 Hz, 1H), 7.23 (dd, J=3.6, 0.46 Hz, 1H), 4.29 (t, J=7.3 Hz, 2H), 
2.01-1.94 (m, 2H), 1.46-1.37 (m, 2H), 0.99 (t, J=7.3 Hz, 3H). 13C NMR (400 MHz, 
CDCl3): δ 189.73, 185.23, 145.61, 134.63, 133.14, 133.06, 127.77, 122.12, 121.23, 
107.98, 59.63, 33.92, 19.97, 13.83. LRMS: (LC/MS-APCI, MeOH) m/e 230.1 (MH+) 
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[5.1.3] Synthesis of 2-butyl-cyclopenta[c]pyridine-4,7-dinitrone (63):  
2-butyl-cyclopenta[c]pyridine-4,7-dicarbaldehyde 
(61) (16 mg,  0.04 mmol) was mixed with N-tert-
butyl hydroxylamine hydrochloride (21 mg, 0.16 
mmol ) and magnesium sulfate (20 mg, 0.16 mmol) 
followed by 2 ml of pyridine. The flask was flushed 
with argon and the reaction mixture was heated at 50 
°C. After 48 h, silica gel thin layer chromatography 
showed no starting material. The product was purified by silica gel column 
chromatography with hexane/ethyl acetate (7:3) as eluent. 12.5 mg (46%) of dinitrone 
(63) was collected along with a small amount of the mononitrone. Rf = 0.23 
(chloroform/methanol 20:1). 
1H NMR: (400 MHz, CDCl3): δ 9.75 (s, 1H), 9.54 (d, J=1.2 Hz, 1H), 8.08 (s, 1H), 7.80 
(d, J=2.9 Hz, 1H), 7.72 (s, 1H), 6.63 (d, J=3.6 Hz, 1H), 4.17 (t, J=7.8 Hz, 2H), 1.99-1.91 
(m, 2H), 1.66 (s, 9H), 1.63 (s, 9H), 1.39 (sextet, J=7.5 Hz, 2H), 0.95 (t, J=7.3 Hz, 3H). 
13C NMR: (400 MHz, CDCl3): δ 137.68, 136.33, 132.92, 128.33, 126.07, 124.52, 
124.43, 116.61, 111.57, 102.54, 71.49, 67.56, 59.81, 33.92, 28.94, 28.67, 20.17, 13.97. 
LRMS: (LC/MS-APCI, MeOH) m/e 372.3 (MH+) 
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[5.1.4] Synthesis of 5-bromo-2-butyl-cylopenta[c]pyridine-4,7-dicarbaldehyde (65):  
2-butyl-cyclopenta[c]pyridine-4,7-dicarbaldehyde (61) (40 mg, 
0.17 mmol) and N-bromosuccinimide (31 mg, 0.17 mmol) were 
dissolved in 1 ml of diethyl ether. Reaction was carried out under 
argon at room temperature. After 30 min, silica gel thin layer 
chromatography showed no reactant and product was purified by 
silica gel column chromatography using hexane/ethyl acetate 
(7:3) as eluent. 41 mg (76%) of product was collected. Rf = 0.15 
(hexane/ethyl acetate 7:3). 
1H NMR (400 MHz, CDCl3): δ 11.42 (s, 1H), 9.84 (s, 1H), 9.07 (d, J=1.6, 1H), 8.08 (d, 
J=1.6, 1H), 7.80 (s, 1H), 4.27 (t, J=7.6 Hz, 2H), 1.99-1.91 (m, 2H), 1.44-1.34 (m, 2H), 
1.00-0.96 (m, 3H). 13C NMR (400 MHz, CDCl3): δ 189.07, 184.26, 144.86, 134.55, 
130.70, 128.64, 127.58, 122.31, 120.65, 91.09, 59.60, 33.52, 19.81, 13.49. LRMS: 
(LC/MS-APCI, MeOH) m/e 308.0 (MH+  [79Br]), 310.0 (MH+ [81Br]). 
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[5.1.5] Synthesis of 2-butyl-5-ethylthio-cyclopenta[c]pyridine-4,7-dicarbaldehyde 
(92): 
2-butyl-cyclopenta[c]pyridine-4,7-dicarbaldehyde (61) (48 mg, 
0.21 mmol ) was dissolved in 10 ml of dry hexane and 0.5 ml of 
dry methylene chloride and was cooled to -70°C while under 
argon. Ethyl sulfenyl chloride (93) (2.2 ml, 0.22 mmol) solution 
in methylene chloride was added slowly over a period of 30 min 
with vigorous stirring and evacuation. After all the ethyl sulfenyl 
chloride solution was added, the mixture was stirred for additional 
30 min and then slowly brought back to room temperature over a 
period of 60-90 min. The red solution turned green. A layer of chloform was added and 
the reaction mixture was extracted with a saturated solution of sodium carbonate. The 
chloroform layer became red. The chloroform layer was concentrated to thick red/brown 
oil and purified with silica gel column chromatography with hexane/ethyl acetate (7:3) as 
eluent. 15 mg (25%) of product (92) was collected. Rf = 0.14 (hexane/ethyl acetate 7:3).  
1H NMR (400 MHz, CDCl3): δ 11.67 (s, 1H), 9.87 (s, 1H), 9.06 (d, J=1.5 Hz, 1H), 8.06 
(d, J=1.6 Hz, 1H), 7.90 (s, 1H), 4.27 (t, J=7.4 Hz, 2H), 2.77 (q, J=7.3 Hz, 2H), 1.99-1.92 
(m, 2H), 1.45-1.35 (m, 2H), 1.22 (t, J=7.3 Hz, 3H), 0.98 (t, J=7.3 Hz, 3H).  
LRMS: (LC/MS-APCI, MeOH) m/e 290.1 (MH+ ). 
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[5.1.6] Synthesis of 2-butyl-5-ethylthio-cyclopenta[c]pyridine-4,7-dinitrone (94): 
2-butyl-5-ethylthio-cyclopenta[c]pyridine-4,7-
dicarbaldehyde (92) (13 mg, 0.04 mmol) was mixed 
with N-t-butylhydroxylamine hydrochloride (28 mg, 
0.22 mmol) and magnesium sulfate (26.8 mg, 0.22 
mmol) in 1.5 ml of pyridine. This reaction mixture 
was stirred at 35 °C under argon for 72 h after which 
it was partitioned between a saturated solution of 
sodium carbonate and chloroform. The chloroform layer was concentrated and the 
resulting mixture was purified by silica gel column chromatography. Initial eluent was 
hexane/ethyl acetate (8:2) and 4 mg (25%) of mononitrone was collected, after which the 
solvent system was changed to hexane/acetone (6:4) to collect 5 mg (26%) of dinitrone 
(94). The product seems to undergo one electron oxidation in the presence of air. 
Therefore it was extracted with saturated solution of sodium thiosulfate before storage.  
Rf = 0.33 (chloroform/methanol 20:1) 
1H NMR (400 MHz, CDCl3): δ 10.00 (s, 1H), 9.85 (d, J=1.2 Hz, 1H), 9.63 (s, 1H), 7.88 
(s, 1H), 7.66 (s, 1H), 4.17 (t, J=7.8 Hz, 2H), 2.68 (q, J=7.3 Hz, 2H), 1.99-1.92 (m, 2H), 
1.68 (s, 9H), 1.63 (s, 9H), 1.43-1.37 (m, 2H), 1.14 (t, J=7.3 Hz, 3H), 0.96 (t, J=7.3 Hz, 
3H). 13C NMR (400 MHz, CDCl3): δ 144.05, 136.56, 131.59, 127.15, 126.69, 126.36, 
125.88, 118.43, 111.42, 106.06, 71.87, 68.05, 59.83, 33.86, 30.55, 28.94, 28.79, 20.18, 
15.08, 13.96. LRMS: (LC/MS-APCI, MeOH) m/e 432.1 (MH+ ). 
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[5.1.7] Synthesis of 2-(propyl imidazole)-cyclopenta[c]pyridine-4,7-dicarbaldehyde 
(71): 
Baldrinal (60) (2.0 g, 8.61 mmol) was dissolved in 4 ml of 
chloroform. To this solution, 1-(3-aminopropyl)-imidazole 
(2.15 g, 17 mmol) was added. After stirring for 10 min at 
room temperature, the color changed from yellow to red 
and silica gel thin layer chromatography showed no 
baldrinal. The product was purified by silica gel column 
chromatography. The eluent for this system was 
triethylamine/methanol/chloroform  (2:1:100). 229 mg 
(8.8%) of red product (71) was collected. Rf = 0.21 (chloroform/methanol 99:1). 
1H NMR (400 MHz, CDCl3): δ 10.21 (s, 1H), 9.91 (s, 1H), 9.00 (s, 1H), 7.99 (d, J=3.6, 
1H), 7.73 (d, J=1.2 Hz, 1H), 7.50 (s, 1H), 7.24 (d, J=3.6 Hz, 1H), 7.12 (s, 1H), 6.95 (s, 
1H), 4.27 (t, J=7.0 Hz, 2H), 4.07 (t, J=7.0 Hz, 2H), 2.51 (quintet, J=7.0, 2H). LRMS: 
(LC/MS-APCI, MeOH) m/e 282.1 (MH+ ). 
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[5.1.8] Synthesis of 2-(propyl imidazole)-cyclopenta[c]pyridine-4,7-dinitrone (72): 
2-(propyl-imidazole)-cyclopenta[c]pyridine-4,7-
dicarbaldehyde (71) (12.6 mg,  0.04 mmol) was mixed 
with N-tert-butyl hydroxylamine (22.5 mg, 0.18 mmol) 
and magnesium sulfate (22 mg, 0,18 mmol)  in 2 ml of 
anhydrous pyridine. The reaction mixture was heated at 
50 °C for 48 h under argon. When silica gel thin layer 
chromatography showed no starting material (71), 
product was purified by silica gel column chromatography. The eluent for this system 
was triethylamine/methanol/chloroform  (2:2:100). 9.1 mg (48%) of red product (72) was 
collected. Rf = 0.25 (chloroform/methanol 9:1). 
1H NMR (400 MHz, CDCl3): δ 9.87 (s, 1H), 9.53 (d, J=0.7 Hz, 1H), 8.06 (s, 1H), 7.74 
(s, 1H), 7.73 (s, 1H), 7.60 (s, 1H), 7.08 (s, 1H), 7.013 (s, 1H), 6.65 (d, J=3.6, 1H), 4.19 (t, 
J=7.0, 2H), 4.01 (t, J=7.0, 2H), 2.45 (quintet, J=7.0, 2H), 1.65 (s, 9H), 1.62 (s, 9H). 13C 
NMR (400 MHz, CDCl3): δ138.01, 136.97, 132.79, 130.31, 129.27, 125.70, 124.50, 
123.93, 119.21, 117.00, 111.81, 103.33, 77.56, 71.68, 67.66, 56.33, 32.88, 28.85, 28.62. 
LRMS: (LC/MS-APCI, MeOH) m/e 424.2 (MH+ ). 
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[5.1.9] Synthesis of 2-(3-(dimethylamino)propyl)-cyclopenta[c]pyridine-4,7-
dicarbaldehyde (74): 
Baldrinal (60) (152 mg, 0.7 mmol) was dissolved in 4 ml of 
chloroform. N,N-dimethylpropane-1,3-diamine (2.0 g, 19 mmol) 
was added. After stirring for 10 min at room temperature, color 
changed from yellow to red. When silica gel thin layer 
chromatography showed no baldrinal, the product was purified 
by silica gel column chromatography using chloroform/methanol (50:1) as eluent. After 
purification, 40 mg (22%) of product was collected. Rf = 0.26 (chloroform/methanol 
99:1). 
1H NMR: (400 MHz, CDCl3): δ 10.23 (s, 1H), 9.92 (s, 1H), 9.08 (s, 1H), 7.98-7.97 (m, 
2H), 7.24 (d, J=3.6 Hz, 1H), 4.42 (t, J=6.5 Hz, 2H), 2.23 (s, 6H), 2.21 (t, J=6.2 Hz, 2H), 
2.08 (quintet, J=6.3 Hz, 2H). LRMS: (LC/MS-APCI, MeOH) m/e 259.1 (MH+). 
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[5.2.0] Synthesis of 2-(3-(dimethylamino)propyl)-cyclopenta[c]pyridine-4,7-dinitrone 
(75): 
2-(3-(dimethylamino)propyl-cyclopenta[c]pyridine-4,7-
dicarbaldehyde (74) (34 mg,  0.13 mmol) was mixed with 
N-tert-butyl hydroxylamine (66.1 mg, 0.52 mmol) and 
magnesium sulfate (63.3 mg, 0.52 mmol)  in 2 ml of 
pyridine. The reaction mixture was heated at 50 °C for 48 
h under argon. Silica gel thin layer chromatography 
showed some mono nitrone. The product was purified by silica gel column 
chromatography. The eluent for this system was triethylamine/methanol/chloroform  
(2:2:100) After purification, 30 mg (57%) of red product collected. Rf = 0.26 
(chloroform/methanol 9:1) 
1H NMR (400 MHz, CDCl3): δ 9.55 (s, 1H), 9.54 (s, 1H), 8.08 (s, 1H), 7.99 (d, J=2.7 Hz, 
1H), 7.74 (s, 1H), 6.64 (d, J=3.5 Hz, 2H), 4.27 (t, J=7.1 Hz, 2H), 2.29 (t, J=6.7 Hz, 2H), 
2.23 (s, 6H), 2.0 (quintet, J=6.9 Hz, 2H), 1.65 (s, 9H), 1.62 (s, 9H). 13C NMR (400 MHz, 
CDCl3): δ 136.62, 136.17, 132.54, 127.71, 125.93, 124.80, 124.61, 116.67, 111.43, 
102.80, 71.49, 67.60, 57.28, 55.72, 45.53, 30.01, 28.89, 28.65. LRMS: (LC/MS-APCI, 
MeOH) m/e 401.5 (MH+). 
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[5.2.1] Synthesis of 2-octadecylamine-cyclopenta[c]pyridine-4,7-dicarbaldehyde 
(87): 
Baldrinal (60) (620 mg, 2.84 mmol) was reacted with 
octadecylamine (1.45 g, 5.38 mmol) in 6 ml of chloroform.  
After stirring for 15 min at room temperature, the solution 
turned thick red. When the starting material had disappeared, 
as determined by thin layer silica gel chromatography, the 
product was purified by silica gel column chromatography 
using hexane/ethyl acetate (7:3) as eluent. 72 mg (6%) of orange product (87) was 
collected. Rf = 0.17 (chloroform/methanol 99:1). 
1H NMR (400 MHz, CDCl3): δ 10.25 (s, 1H), 9.92 (s, 1H), 9.03 (s, 1H), 7.97 (d, J=3.7 
Hz, 1H), 7.84 (d, J=1.4 Hz, 1H), 7.23 (d, J=3.5 Hz, 1H), 4.28 (t, J=7.4 Hz, 2H), 2.02-
1.94 (m, 2H), 1.24 (m, 32H), 0.89-0.85 (m, 3H). LRMS: (LC/MS-APCI, MeOH) m/e 
426.2 (MH+ ). 
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[5.2.2] Synthesis of 2-octadecylamine-cyclopenta[c]pyridine-4,7-dinitrone (88): 
2-octadecyl-cyclopenta[c]pyridine-4,7-
dicarbaldehyde (87) (28 mg, 0.06 mmol) was 
mixed with N-tert-butyl hydroxylamine (37 mg, 
0.3 mmol) and magnesium sulfate (36 mg, 0.3 
mmol) in 2 ml of pyridine. The reaction was heated 
at 80°C for 48 h. When silica gel thin layer 
chromatography showed no starting material, the 
product was purified by silica gel column chromatography using CHCl3/MeOH (20:1) as 
eluent. 15 mg (40%) of product (88) was collected. Rf = 0.32 (chloroform/methanol 
20:1). 
1H NMR (400 MHz, CDCl3): δ 9.77 (s, 1H), 9.55 (s, 1H), 8.09 (s, 1H), 7.79 (d, J=3.2 
Hz, 1H), 7.72 (s, 1H), 6.64 (d, J=3.6 Hz, 1H), 4.16 (t, J=7.8 Hz, 2H), 1.96 (quintet, 
J=7.3 Hz, 2H), 1.67 (s, 9H), 1.64 (s, 9H), 1.25 (m, 30 H), 0.89-0.85 (m, 3H).  
13C NMR (400 MHz, CDCl3): δ 137.74, 136.28, 132.80, 128.26, 126.07, 124.49, 124.41, 
116.63, 111.62, 102.50, 71.49, 67.56, 60.05, 32.26, 32.05, 30.03, 29.99, 29.92, 29.85, 
29.79, 29.69, 29.53, 28.96, 28.68, 26.87, 23.02, 14.44. LRMS: (LC/MS-APCI, MeOH) 
m/e 568.2 (MH+). 
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[5.2.3] Synthesis of 2-(6-hexanol)-cyclopenta[c]pyridine-4,7-dicarbaldehyde (90): 
Baldrinal (60) (150 mg, 0.68 mmol) was mixed with 6-amino-1-
hexanol (152 mg, 1.29 mmol) in 4 ml of chloroform. After 
stirring for 15 min at room temperature, the solution turned into 
thick red liquid. When silica gel thin layer chromatography 
showed no baldrinal, the product was purified by silica gel 
column chromatography using chloroform/methanol (100:1) as 
eluent. 17 mg (9%) of orange product (90) was collected. Rf = 0.11 (chloroform/methanol 
99:1). 
1H NMR (400 MHz, CDCl3): δ 10.22 (s, 1H), 9.88 (s, 1H), 9.01 (s, 1H), 7.96 (d, J=3.6 
Hz, 1H), 7.84 (d, J=1.4 Hz, 1H), 7.22 (d, J=3.6 Hz, 1H), 4.29 (t, J=7.2 Hz, 2H), 3.63 (m, 
2H), 1.99 (quintet, J=7.3 Hz, 2H), 1.86 (s, 1H), 1.59-1.53 (m, 2H), 1.46-1.43 (m, 2H), 
1.42-1.36 (m, 2H). LRMS: (LC/MS-APCI, MeOH) m/e 274.1 (MH+). 
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[5.2.4] Synthesis of 2-(6-hexanol)-cyclopenta[c]pyridine-4,7-dinitrone (91): 
2-(6-hexanol)-cyclopenta[c]pyridine-4,7-
dicarbaldehyde (90) (17 mg, 0.06 mmol) was mixed 
with N-tert-butyl hydroxylamine (30.6 mg, 0.24 mmol) 
and magnesium sulfate (29.4 mg, 0.24 mmol) in 2 ml of 
pyridine. Reaction flask was flushed with argon. Heated 
at 50 °C for 48 h. Product was purified via silica gel 
column chromatography with chloroform/methanol 
(50:1) as eluent. 15 mg (58%) of product collected. Rf = 
0.21 (chloroform/methanol 20:1). 
1H NMR (400 MHz, CDCl3): δ 9.94 (s, 1H), 9.55 (d, J=1.2 Hz, 1H), 8.09 (s, 1H), 7.71 
(s, 1H), 7.65 (d, J=3.5, 1H), 6.64 (d, J=3.6 Hz, 1H), 4.24 (t, J=6.9 Hz, 2H), 3.60 (t, 
J=5.5 Hz, 2H), 1.99 (quintet, J=6.9 Hz, 2H), 1.66 (s, 9H), 1.63 (s, 9H), 1.57-1.52 (m, 
4H), 1.37-1.30 (m, 2H). 13C NMR (400 MHz, CDCl3): δ 136.59, 136.51, 132.92, 129.19, 
125.78, 124.28, 123.76, 116.42, 111.13, 102.34, 71.22, 67.19, 61.50, 58.44, 32.22, 30.92, 
28.56, 28.32, 24.86, 24.22. LRMS: (LC/MS-APCI, MeOH) m/e 416.5 (MH+). 
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[5.2.5] Synthesis of Spermine analogue of pseudoazulenyl dinitrone (86): 
2-(3-(dimethylamino)propyl)-cyclopenta[c] 
pyridine-4,7-dinitrone (75) (3 mg, 0.007 mmol) 
was mixed with 1,4-diiodobutane (0.5 ml, 11 
mmol). This mixture was stirred at room 
temperature for 2 h in the dark, since the product 
was photosensitive. After 2 h, silica gel thin 
layer chromatography showed no starting 
material. Reaction mixture was successively 
partitioned between hexane and acetonitrile to 
remove excess of 1,4-diiodobutane in order to 
get (84).  This product, without further purification, was reacted with N,N,N'N'-
tetramethyl propanediamine (85) (1 ml, excess) in acetonitrile for 1 h at room 
temperature in the dark. Acetonitrile and N,N,N'N'-tetramethyl propanediamine were 
removed under vacuum to get spermine analogue (86).  
1H NMR (400 MHz, MeOD): δ 10.04 (s, 1H), 9.90 (s, 1H), 8.63 (s, 1H), 8.35 (s, 1H), 
8.16 (d, J=4.7 Hz, 1H), 7.40 (d, J=4.6 Hz, 1H), 4.74 (t, J=7.4 Hz, 2H), 4.30 (m, 2H), 
3.66-3.62 (m, 2H), 3.58-3.56 (m, 2H), 3.50-3.48 (m, 2H), 3.46-3.35 (m, 2H), 3.22 (s, 
6H), 3.16 (s, 12H), 2.72 (m, 2H), 2.54 (t, J=7.4 Hz, 2H), 1.99-1.95 (m, 4H), 1.73 (s, 9H), 
1.69 (s, 9H). LRMS: (LC/MS-APCI, MeOH) m/e 293.2 (M2+). 
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[5.2.6] Cyclic voltammetry 
 Cyclic voltammetry experiments were performed at Dr. Angel Keiffer’s lab at 
University of Miami, Miami, Florida. Both the compounds, 2-butyl-5-ethylthio-
cyclopenta[c]pyridine-4,7-dinitrone (94) and STAZN (32) were tested under the same 
conditions. Cyclic voltammetry were performed on a solution of compounds (94) and 
(32) in CH2Cl2 at a concentration of 100 mM with scan rate of 100 mV s-1. The working 
electrode used in this experiment was a glassy carbon electrode and the electrolyte was 
tetrabutylammonium hexaflurophosphate (TBAPF6) at a concentration of 100 mM. 
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